CHEBI ONTOLOGY - ANNOTATIONS |
|
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
|
Term: | propellant |
|
Accession: | CHEBI:76414
|
browse the term
|
Definition: | A compressed gas or liquid with a boiling point lower than room temperature which to used to propel and dispense liquids such as deodorants, insecticides, paints, etc. from aerosol cans. |
Synonyms: | related_synonym: | propellants |
| xref: | PMID:22519407; PMID:24001847 |
|
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
increases activity |
ISO |
secoisolariciresinol results in increased activity of NR1I2 protein |
CTD |
PMID:15885729 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
|
G |
Abcb1b |
ATP-binding cassette, subfamily B (MDR/TAP), member 1B |
increases expression |
EXP |
1-nitropropane results in increased expression of ABCB1B mRNA |
CTD |
PMID:17070881 |
|
NCBI chr 4:25,242,761...25,325,194
Ensembl chr 4:25,242,798...25,325,199
|
|
G |
Acmsd |
aminocarboxymuconate semialdehyde decarboxylase |
increases expression |
EXP |
1-nitropropane results in increased expression of ACMSD mRNA |
CTD |
PMID:17070881 |
|
NCBI chr13:39,200,486...39,244,337
Ensembl chr13:39,200,314...39,245,209
|
|
G |
Acsl3 |
acyl-CoA synthetase long-chain family member 3 |
decreases expression |
EXP |
1-nitropropane results in decreased expression of ACSL3 mRNA |
CTD |
PMID:17070881 |
|
NCBI chr 9:80,140,996...80,164,636
Ensembl chr 9:80,115,112...80,164,627
|
|
G |
Aen |
apoptosis enhancing nuclease |
increases expression |
EXP |
1-nitropropane results in increased expression of AEN mRNA |
CTD |
PMID:17070881 |
|
NCBI chr 1:132,815,094...132,824,522
Ensembl chr 1:132,815,142...132,824,523
|
|
G |
Akr7a3 |
aldo-keto reductase family 7 member A3 |
decreases expression |
EXP |
1-nitropropane results in decreased expression of AKR7A3 mRNA |
CTD |
PMID:17070881 |
|
NCBI chr 5:151,590,968...151,601,394
Ensembl chr 5:151,584,479...151,601,394
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
increases expression |
EXP |
1-nitropropane results in increased expression of ALDH1A1 mRNA |
CTD |
PMID:17070881 |
|
NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961
|
|
G |
Aldh1a7 |
aldehyde dehydrogenase family 1, subfamily A7 |
increases expression |
EXP |
1-nitropropane results in increased expression of ALDH1A4 mRNA |
CTD |
PMID:17070881 |
|
NCBI chr 1:218,201,443...218,241,410
Ensembl chr 1:218,201,472...218,248,906
|
|
G |
Apoa2 |
apolipoprotein A2 |
increases expression |
EXP |
1-nitropropane results in increased expression of APOA2 mRNA |
CTD |
PMID:17070881 |
|
NCBI chr13:83,644,460...83,646,358
Ensembl chr13:83,644,470...83,646,355
|
|
G |
Apoa4 |
apolipoprotein A4 |
decreases expression |
EXP |
1-nitropropane results in decreased expression of APOA4 mRNA |
CTD |
PMID:17070881 |
|
NCBI chr 8:46,539,083...46,541,464
Ensembl chr 8:46,539,082...46,541,469
|
|
G |
Apoc3 |
apolipoprotein C3 |
increases expression |
EXP |
1-nitropropane results in increased expression of APOC3 mRNA |
CTD |
PMID:17070881 |
|
NCBI chr 8:46,531,478...46,533,658
Ensembl chr 8:46,531,478...46,533,583
|
|
G |
Atp6v1d |
ATPase H+ transporting V1 subunit D |
increases expression |
EXP |
1-nitropropane results in increased expression of ATP6V1D mRNA |
CTD |
PMID:17070881 |
|
NCBI chr 6:97,656,725...97,672,211
Ensembl chr 6:97,656,576...97,672,303
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression |
EXP |
1-nitropropane results in increased expression of BAX mRNA |
CTD |
PMID:17070881 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Btg2 |
BTG anti-proliferation factor 2 |
decreases expression |
EXP |
1-nitropropane results in decreased expression of BTG2 mRNA |
CTD |
PMID:17070881 |
|
NCBI chr13:45,531,881...45,535,642
Ensembl chr13:45,531,925...45,535,628
|
|
G |
C7 |
complement C7 |
decreases expression |
EXP |
1-nitropropane results in decreased expression of C7 mRNA |
CTD |
PMID:17070881 |
|
NCBI chr 2:54,088,116...54,165,102
Ensembl chr 2:54,088,116...54,158,535
|
|
G |
Cblc |
Cbl proto-oncogene C |
decreases expression |
EXP |
1-nitropropane results in decreased expression of CBLC mRNA |
CTD |
PMID:17070881 |
|
NCBI chr 1:79,439,975...79,456,755
Ensembl chr 1:79,439,977...79,456,755
|
|
G |
Ccng1 |
cyclin G1 |
increases expression |
EXP |
1-nitropropane results in increased expression of CCNG1 mRNA |
CTD |
PMID:17070881 |
|
NCBI chr10:25,176,231...25,182,604
Ensembl chr10:25,176,234...25,181,641
|
|
G |
Cd276 |
Cd276 molecule |
decreases expression |
EXP |
1-nitropropane results in decreased expression of CD276 mRNA |
CTD |
PMID:17070881 |
|
NCBI chr 8:58,937,751...58,968,082
Ensembl chr 8:58,937,751...58,968,380
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
decreases expression |
EXP |
1-nitropropane results in decreased expression of CDKN1A mRNA |
CTD |
PMID:17070881 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cpq |
carboxypeptidase Q |
decreases expression |
EXP |
1-nitropropane results in decreased expression of CPQ mRNA |
CTD |
PMID:17070881 |
|
NCBI chr 7:64,264,025...64,830,867
Ensembl chr 7:64,264,081...64,724,546
|
|
G |
Cryab |
crystallin, alpha B |
decreases expression |
EXP |
1-nitropropane results in decreased expression of CRYAB mRNA |
CTD |
PMID:17070881 |
|
NCBI chr 8:51,093,441...51,099,161
Ensembl chr 8:51,093,441...51,099,157
|
|
G |
Cyp2c13 |
cytochrome P450, family 2, subfamily c, polypeptide 13 |
decreases expression |
EXP |
1-nitropropane results in decreased expression of CYP2C13 mRNA |
CTD |
PMID:17070881 |
|
NCBI chr 1:238,786,764...238,867,195
Ensembl chr 1:238,786,765...238,867,191
|
|
G |
Cyp4f5 |
cytochrome P450, family 4, subfamily f, polypeptide 5 |
increases expression |
EXP |
1-nitropropane results in increased expression of CYP4F5 mRNA |
CTD |
PMID:17070881 |
|
NCBI chr 7:11,544,040...11,558,982
Ensembl chr 7:11,544,082...11,558,978
|
|
G |
Ddah1 |
dimethylarginine dimethylaminohydrolase 1 |
decreases expression |
EXP |
1-nitropropane results in decreased expression of DDAH1 mRNA |
CTD |
PMID:17070881 |
|
NCBI chr 2:234,667,499...234,800,322
Ensembl chr 2:234,667,491...234,799,339
|
|
G |
Epcam |
epithelial cell adhesion molecule |
decreases expression |
EXP |
1-nitropropane results in decreased expression of EPCAM mRNA |
CTD |
PMID:17070881 |
|
NCBI chr 6:6,880,142...6,896,103
Ensembl chr 6:6,878,237...6,896,127
|
|
G |
Ephx1 |
epoxide hydrolase 1 |
decreases expression |
EXP |
1-nitropropane results in decreased expression of EPHX1 mRNA |
CTD |
PMID:17070881 |
|
NCBI chr13:92,714,315...92,744,124
Ensembl chr13:92,714,315...92,790,235
|
|
G |
Fas |
Fas cell surface death receptor |
increases expression |
EXP |
1-nitropropane results in increased expression of FAS mRNA |
CTD |
PMID:17070881 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Fhit |
fragile histidine triad diadenosine triphosphatase |
increases expression |
EXP |
1-nitropropane results in increased expression of FHIT mRNA |
CTD |
PMID:17070881 |
|
NCBI chr15:13,935,029...15,442,620
Ensembl chr15:13,934,995...15,442,340
|
|
G |
Gria3 |
glutamate ionotropic receptor AMPA type subunit 3 |
decreases expression |
EXP |
1-nitropropane results in decreased expression of GRIA3 mRNA |
CTD |
PMID:17070881 |
|
NCBI chr X:120,238,515...120,504,106
Ensembl chr X:120,238,534...120,504,096
|
|
G |
Gstm1 |
glutathione S-transferase mu 1 |
decreases expression |
EXP |
1-nitropropane results in decreased expression of GSTM1 mRNA |
CTD |
PMID:17070881 |
|
NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411
|
|
G |
Hsd17b6 |
hydroxysteroid (17-beta) dehydrogenase 6 |
increases expression |
EXP |
1-nitropropane results in increased expression of HSD17B6 mRNA |
CTD |
PMID:17070881 |
|
NCBI chr 7:422,466...442,008
Ensembl chr 7:422,480...442,425
|
|
G |
Il2ra |
interleukin 2 receptor subunit alpha |
decreases expression |
EXP |
1-nitropropane results in decreased expression of IL2RA mRNA |
CTD |
PMID:17070881 |
|
NCBI chr17:66,849,974...66,898,665
Ensembl chr17:66,849,974...66,898,697
|
|
G |
Mgmt |
O-6-methylguanine-DNA methyltransferase |
increases expression |
EXP |
1-nitropropane results in increased expression of MGMT mRNA |
CTD |
PMID:17070881 |
|
NCBI chr 1:191,710,980...191,937,760
Ensembl chr 1:191,710,930...191,937,756
|
|
G |
Nupr1 |
nuclear protein 1, transcriptional regulator |
increases expression |
EXP |
1-nitropropane results in increased expression of NUPR1 mRNA |
CTD |
PMID:17070881 |
|
NCBI chr 1:181,213,292...181,215,327
|
|
G |
Phlda3 |
pleckstrin homology-like domain, family A, member 3 |
decreases expression |
EXP |
1-nitropropane results in decreased expression of PHLDA3 mRNA |
CTD |
PMID:17070881 |
|
NCBI chr13:47,193,250...47,196,335
Ensembl chr13:47,193,086...47,196,335
|
|
G |
Rhobtb2 |
Rho-related BTB domain containing 2 |
increases expression |
EXP |
1-nitropropane results in increased expression of RHOBTB2 mRNA |
CTD |
PMID:17070881 |
|
NCBI chr15:44,868,251...44,888,436
Ensembl chr15:44,870,376...44,888,651
|
|
G |
Serpina7 |
serpin family A member 7 |
decreases expression |
EXP |
1-nitropropane results in decreased expression of SERPINA7 mRNA |
CTD |
PMID:17070881 |
|
NCBI chr X:102,663,242...102,722,319
Ensembl chr X:102,663,405...102,669,040
|
|
G |
Slc16a10 |
solute carrier family 16 member 10 |
increases expression |
EXP |
1-nitropropane results in increased expression of SLC16A10 mRNA |
CTD |
PMID:17070881 |
|
NCBI chr20:43,454,819...43,567,839
Ensembl chr20:43,459,709...43,567,839
|
|
G |
Spink1 |
serine peptidase inhibitor, Kazal type 1 |
increases expression |
EXP |
1-nitropropane results in increased expression of SPINK1 mRNA |
CTD |
PMID:17070881 |
|
NCBI chr18:35,870,723...35,882,693
Ensembl chr18:35,824,550...35,882,642
|
|
G |
Sugct |
succinylCoA:glutarate-CoA transferase |
decreases expression |
EXP |
1-nitropropane results in decreased expression of SUGCT mRNA |
CTD |
PMID:17070881 |
|
NCBI chr17:47,376,392...48,234,362
Ensembl chr17:47,376,521...48,234,376
|
|
G |
Sulf2 |
sulfatase 2 |
increases expression |
EXP |
1-nitropropane results in increased expression of SULF2 mRNA |
CTD |
PMID:17070881 |
|
NCBI chr 3:154,822,079...154,904,566
Ensembl chr 3:154,822,085...154,904,415
|
|
G |
Sult2a1 |
sulfotransferase family 2A member 1 |
increases expression |
EXP |
1-nitropropane results in increased expression of SULT2A1 mRNA |
CTD |
PMID:17070881 |
|
NCBI chr 1:75,451,178...75,508,142
Ensembl chr 1:74,911,100...75,508,134
|
|
G |
Zmat3 |
zinc finger, matrin type 3 |
decreases expression |
EXP |
1-nitropropane results in decreased expression of ZMAT3 mRNA |
CTD |
PMID:17070881 |
|
NCBI chr 2:115,106,050...115,136,863
Ensembl chr 2:115,106,966...115,136,863
|
|
|
G |
Capn1 |
calpain 1 |
multiple interactions |
ISO |
aloxistatin inhibits the reaction [CAPN1 protein results in increased degradation of and results in decreased expression of SMN2 protein alternative form] |
CTD |
PMID:30910806 |
|
NCBI chr 1:203,275,912...203,300,848
Ensembl chr 1:203,277,344...203,300,177
|
|
G |
Capn7 |
calpain 7 |
multiple interactions |
ISO |
aloxistatin inhibits the reaction [CAPN7 protein results in increased degradation of and results in decreased expression of SMN2 protein alternative form] |
CTD |
PMID:30910806 |
|
NCBI chr16:6,545,630...6,581,908
Ensembl chr16:6,545,731...6,581,905
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO EXP |
[aloxistatin co-treated with pepstatin] inhibits the reaction [[vistusertib co-treated with Chloroquine] results in increased activity of CASP3 protein] [Swainsonine co-treated with aloxistatin] results in increased cleavage of CASP3 protein |
CTD |
PMID:26853465 PMID:33186601 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
ISO |
aloxistatin inhibits the reaction [syringic acid analog results in increased secretion of CASP9 protein] |
CTD |
PMID:34523043 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Ctsb |
cathepsin B |
multiple interactions |
ISO |
[aloxistatin co-treated with pepstatin] results in decreased expression of CTSB protein; aloxistatin inhibits the reaction [CTSB protein results in increased degradation of and results in decreased expression of SMN2 protein alternative form] |
CTD |
PMID:30910806 PMID:32186374 |
|
NCBI chr15:37,389,636...37,410,508
Ensembl chr15:37,389,629...37,410,500
|
|
G |
Ctsd |
cathepsin D |
multiple interactions |
ISO |
[aloxistatin co-treated with pepstatin] results in decreased expression of CTSD protein |
CTD |
PMID:32186374 |
|
NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488
|
|
G |
Ctsl |
cathepsin L |
multiple interactions |
ISO |
aloxistatin inhibits the reaction [CTSL protein results in increased degradation of and results in decreased expression of SMN2 protein alternative form] |
CTD |
PMID:30910806 |
|
NCBI chr17:764,370...770,533
Ensembl chr17:764,309...770,548
|
|
G |
Ddx3x |
DEAD-box helicase 3, X-linked |
multiple interactions |
ISO |
aloxistatin inhibits the reaction [[quizartinib co-treated with spautin-1] results in increased degradation of DDX3X protein] |
CTD |
PMID:30821613 |
|
NCBI chr X:9,479,532...9,493,455
Ensembl chr X:9,479,532...9,493,168
|
|
G |
Eif4a1 |
eukaryotic translation initiation factor 4A1 |
multiple interactions |
ISO |
aloxistatin inhibits the reaction [[quizartinib co-treated with spautin-1] results in increased degradation of EIF4A1 protein] |
CTD |
PMID:30821613 |
|
NCBI chr10:54,384,345...54,389,853
Ensembl chr10:54,384,347...54,389,858
|
|
G |
Eif4h |
eukaryotic translation initiation factor 4H |
multiple interactions |
ISO |
aloxistatin inhibits the reaction [[quizartinib co-treated with spautin-1] results in increased degradation of EIF4H protein] |
CTD |
PMID:30821613 |
|
NCBI chr12:22,083,155...22,099,876
Ensembl chr12:22,082,835...22,099,876
|
|
G |
Gapdh |
glyceraldehyde-3-phosphate dehydrogenase |
multiple interactions |
ISO |
aloxistatin inhibits the reaction [syringic acid analog results in increased secretion of GAPDH protein] |
CTD |
PMID:34523043 |
|
NCBI chr 4:157,962,312...157,967,158
Ensembl chr 4:157,962,343...157,966,235
|
|
G |
Lamp2 |
lysosomal-associated membrane protein 2 |
multiple interactions |
ISO |
[aloxistatin co-treated with pepstatin] results in increased expression of LAMP2 protein |
CTD |
PMID:32186374 |
|
NCBI chr X:117,173,097...117,222,090
Ensembl chr X:117,057,606...117,260,522
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
multiple interactions |
ISO |
[aloxistatin co-treated with pepstatin] inhibits the reaction [Biological Factors deficiency results in increased degradation of MAP1LC3B protein modified form]; [aloxistatin co-treated with pepstatin] inhibits the reaction [Biological Factors deficiency results in increased lipidation of MAP1LC3B protein]; [aloxistatin co-treated with pepstatin] inhibits the reaction [Dronabinol results in increased degradation of MAP1LC3B protein modified form]; [aloxistatin co-treated with pepstatin] inhibits the reaction [Dronabinol results in increased lipidation of MAP1LC3B protein]; [aloxistatin co-treated with pepstatin] promotes the reaction [ABTL0812 results in increased expression of and results in increased lipidation of MAP1LC3B protein]; [aloxistatin co-treated with pepstatin] promotes the reaction [Brefeldin A results in increased expression of and results in increased lipidation of MAP1LC3B protein]; [aloxistatin co-treated with pepstatin] promotes the reaction [N-((1R,2S)-2-hydroxy-1-hydroxymethyl-2-(2-tridecyl-1-cyclopropenyl)ethyl)octanamide results in increased expression of and results in increased lipidation of MAP1LC3B protein]; [aloxistatin co-treated with pepstatin] results in decreased degradation of MAP1LC3B protein modified form [aloxistatin co-treated with pepstatin] inhibits the reaction [Biological Factors deficiency results in increased degradation of MAP1LC3B protein modified form]; [aloxistatin co-treated with pepstatin] inhibits the reaction [Biological Factors deficiency results in increased lipidation of MAP1LC3B protein]; [aloxistatin co-treated with pepstatin] inhibits the reaction [Dronabinol results in increased degradation of MAP1LC3B protein modified form]; [aloxistatin co-treated with pepstatin] inhibits the reaction [Dronabinol results in increased lipidation of MAP1LC3B protein]; [aloxistatin co-treated with pepstatin] results in increased expression of MAP1LC3B protein |
CTD |
PMID:26483381 PMID:27635674 PMID:32397857 |
|
NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
|
|
G |
Sqstm1 |
sequestosome 1 |
multiple interactions |
ISO |
[aloxistatin co-treated with pepstatin] results in increased expression of SQSTM1 protein [aloxistatin co-treated with pepstatin] results in increased expression of SQSTM1 protein; [Dronabinol co-treated with aloxistatin co-treated with pepstatin] results in increased expression of SQSTM1 protein; [HU 211 co-treated with aloxistatin co-treated with pepstatin] results in increased expression of SQSTM1 protein |
CTD |
PMID:26483381 PMID:32186374 PMID:32773031 |
|
NCBI chr10:34,525,517...34,536,685
Ensembl chr10:34,525,519...34,536,673
|
|
|
G |
Adrb2 |
adrenoceptor beta 2 |
decreases response to substance |
ISO |
ADRB2 protein results in decreased susceptibility to Busulfan |
CTD |
PMID:7202579 |
|
NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512
|
|
G |
Ahr |
aryl hydrocarbon receptor |
increases expression |
ISO |
Busulfan results in increased expression of AHR mRNA |
CTD |
PMID:35641671 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Anp32b |
acidic nuclear phosphoprotein 32 family member B |
multiple interactions |
ISO |
[clofarabine co-treated with fludarabine co-treated with Busulfan] results in increased cleavage of ANP32B protein |
CTD |
PMID:20933509 |
|
NCBI chr 5:60,743,077...60,765,726
Ensembl chr 5:60,743,443...60,765,717
|
|
G |
Apex1 |
apurinic/apyrimidinic endodeoxyribonuclease 1 |
increases response to substance |
ISO |
APEX1 protein mutant form results in increased susceptibility to Busulfan |
CTD |
PMID:19470598 |
|
NCBI chr15:24,144,595...24,146,785
Ensembl chr15:24,144,362...24,146,785
|
|
G |
Ar |
androgen receptor |
multiple interactions |
ISO |
Busulfan inhibits the reaction [Metribolone results in increased activity of AR protein] |
CTD |
PMID:18324785 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Arhgdia |
Rho GDP dissociation inhibitor alpha |
multiple interactions affects response to substance |
ISO |
ARHGDIA mRNA affects the reaction [Busulfan results in increased activity of CASP3 protein] ARHGDIA mRNA affects the susceptibility to Busulfan |
CTD |
PMID:17264767 |
|
NCBI chr10:105,854,526...105,858,020
Ensembl chr10:105,854,533...105,858,023
|
|
G |
Atf4 |
activating transcription factor 4 |
multiple interactions increases expression |
ISO |
4-phenylbutyric acid inhibits the reaction [Busulfan results in increased expression of ATF4 protein] Busulfan results in increased expression of ATF4 mRNA |
CTD |
PMID:35533795 PMID:35641671 |
|
NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446
|
|
G |
Atm |
ATM serine/threonine kinase |
multiple interactions |
ISO |
[clofarabine co-treated with fludarabine co-treated with Busulfan] results in increased phosphorylation of ATM protein |
CTD |
PMID:20933509 |
|
NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437
|
|
G |
Bmp4 |
bone morphogenetic protein 4 |
decreases expression |
EXP |
Busulfan results in decreased expression of BMP4 mRNA |
CTD |
PMID:15786497 |
|
NCBI chr15:19,618,538...19,633,494
Ensembl chr15:19,618,542...19,623,306
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases activity |
ISO |
[clofarabine co-treated with fludarabine co-treated with Busulfan] results in increased cleavage of CASP3 protein; [decitabine co-treated with Busulfan] results in increased activity of CASP3 protein; ARHGDIA mRNA affects the reaction [Busulfan results in increased activity of CASP3 protein] |
CTD |
PMID:17264767 PMID:18339423 PMID:19732952 PMID:20933509 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
increases activity multiple interactions |
ISO |
Busulfan results in increased activity of CASP8 protein [decitabine co-treated with Busulfan] results in increased activity of CASP8 protein; pifithrin inhibits the reaction [[decitabine co-treated with Busulfan] results in increased activity of CASP8 protein] |
CTD |
PMID:18339423 PMID:19732952 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
ISO |
[clofarabine co-treated with fludarabine co-treated with Busulfan] results in increased cleavage of CASP9 protein; pifithrin inhibits the reaction [[decitabine co-treated with Busulfan] results in increased activity of CASP9 protein] |
CTD |
PMID:19732952 PMID:20933509 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cdc25b |
cell division cycle 25B |
multiple interactions |
ISO |
[clofarabine co-treated with fludarabine co-treated with Busulfan] results in increased phosphorylation of CDC25B protein |
CTD |
PMID:20933509 |
|
NCBI chr 3:118,407,127...118,417,272
Ensembl chr 3:118,407,128...118,417,272
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
decreases expression |
ISO |
Busulfan results in decreased expression of CDK2 mRNA |
CTD |
PMID:15388331 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
decreases expression |
ISO |
Busulfan results in decreased expression of CDK4 mRNA |
CTD |
PMID:15388331 |
|
NCBI chr 7:62,885,647...62,889,562
Ensembl chr 7:62,883,105...62,942,403
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression multiple interactions |
ISO |
Busulfan results in increased expression of CDKN1A protein [clofarabine co-treated with fludarabine co-treated with Busulfan] results in increased expression of CDKN1A protein |
CTD |
PMID:16882877 PMID:20933509 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
increases expression |
ISO |
Busulfan results in increased expression of CDKN2A mRNA |
CTD |
PMID:14500376 |
|
NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149
|
|
G |
Chek1 |
checkpoint kinase 1 |
multiple interactions |
ISO |
[clofarabine co-treated with fludarabine co-treated with Busulfan] results in increased phosphorylation of CHEK1 protein |
CTD |
PMID:20933509 |
|
NCBI chr 8:36,420,565...36,443,477
Ensembl chr 8:36,420,569...36,441,009
|
|
G |
Chek2 |
checkpoint kinase 2 |
multiple interactions |
ISO |
[clofarabine co-treated with fludarabine co-treated with Busulfan] results in increased phosphorylation of CHEK2 protein |
CTD |
PMID:20933509 |
|
NCBI chr12:45,788,823...45,821,382
Ensembl chr12:45,788,827...45,821,286
|
|
G |
Cldn11 |
claudin 11 |
decreases expression multiple interactions |
ISO |
Busulfan results in decreased expression of CLDN11 mRNA; Busulfan results in decreased expression of CLDN11 protein 4-phenylbutyric acid inhibits the reaction [Busulfan results in decreased expression of CLDN11 protein] |
CTD |
PMID:35533795 |
|
NCBI chr 2:112,207,745...112,221,050
Ensembl chr 2:112,207,745...112,221,050
|
|
G |
Col4a1 |
collagen type IV alpha 1 chain |
affects expression |
ISO |
Busulfan affects the expression of COL4A1 mRNA |
CTD |
PMID:15941629 |
|
NCBI chr16:78,183,533...78,294,412
Ensembl chr16:78,183,533...78,294,412
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
decreases activity |
ISO |
Busulfan results in decreased activity of CYP1A1 protein |
CTD |
PMID:33814510 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
multiple interactions |
ISO |
[GSTM1 protein co-treated with CYP2C9 protein] results in increased susceptibility to [Busulfan co-treated with Cyclophosphamide] |
CTD |
PMID:28744217 |
|
NCBI chr 1:236,762,719...236,799,069
Ensembl chr 1:236,762,842...236,799,066
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions increases expression |
ISO |
4-phenylbutyric acid inhibits the reaction [Busulfan results in increased expression of DDIT3 protein] |
CTD |
PMID:35533795 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
multiple interactions increases phosphorylation |
ISO |
4-phenylbutyric acid inhibits the reaction [Busulfan results in increased phosphorylation of EIF2AK3 protein] |
CTD |
PMID:35533795 |
|
NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911
|
|
G |
Eif2s1 |
eukaryotic translation initiation factor 2 subunit alpha |
increases phosphorylation multiple interactions |
ISO |
Busulfan results in increased phosphorylation of EIF2S1 protein 4-phenylbutyric acid inhibits the reaction [Busulfan results in increased phosphorylation of EIF2S1 protein] |
CTD |
PMID:35533795 |
|
NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225
|
|
G |
Faslg |
Fas ligand |
decreases expression |
ISO |
Busulfan results in decreased expression of FASL mRNA |
CTD |
PMID:15388331 |
|
NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
|
|
G |
Fgf8 |
fibroblast growth factor 8 |
decreases expression |
EXP |
Busulfan results in decreased expression of FGF8 mRNA |
CTD |
PMID:15786497 |
|
NCBI chr 1:244,584,477...244,590,359
Ensembl chr 1:244,584,652...244,590,359
|
|
G |
Gdnf |
glial cell derived neurotrophic factor |
affects expression increases expression |
ISO |
Busulfan affects the expression of GDNF mRNA Busulfan results in increased expression of GDNF mRNA |
CTD |
PMID:20684317 PMID:22082982 PMID:26524245 |
|
NCBI chr 2:56,893,992...56,919,935
Ensembl chr 2:56,895,010...56,917,209
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
decreases expression multiple interactions |
ISO |
Busulfan results in decreased expression of GJA1 mRNA; Busulfan results in decreased expression of GJA1 protein 4-phenylbutyric acid inhibits the reaction [Busulfan results in decreased expression of GJA1 protein] |
CTD |
PMID:35533795 |
|
NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582
|
|
G |
Gpx4 |
glutathione peroxidase 4 |
multiple interactions decreases expression |
ISO |
Busulfan results in decreased expression of and results in decreased activity of GPX4 protein; Deferoxamine inhibits the reaction [Busulfan results in decreased expression of GPX4 protein]; ferrostatin-1 inhibits the reaction [Busulfan results in decreased expression of and results in decreased activity of GPX4 protein]; sulforaphane inhibits the reaction [Busulfan results in decreased expression of and results in decreased activity of GPX4 protein] |
CTD |
PMID:32416107 |
|
NCBI chr 7:9,650,186...9,652,982
Ensembl chr 7:9,650,185...9,652,982
|
|
G |
Gsta1 |
glutathione S-transferase alpha 1 |
multiple interactions affects response to substance affects metabolic processing affects abundance decreases response to substance |
ISO |
GSTA1 protein affects the metabolism of [Busulfan co-treated with Glutathione] GSTA1 polymorphism affects the susceptibility to Busulfan GSTA1 gene polymorphism affects the metabolism of Busulfan; GSTA1 protein affects the metabolism of Busulfan GSTA1 gene polymorphism affects the abundance of Busulfan GSTA1 protein results in decreased susceptibility to Busulfan |
CTD |
PMID:8886613 PMID:10437668 PMID:10570028 PMID:12429583 PMID:20672371 PMID:21135089 PMID:21215809 PMID:21441958 More...
|
|
NCBI chr 9:23,703,476...23,720,121
Ensembl chr 9:23,703,477...23,720,121
|
|
G |
Gstm1 |
glutathione S-transferase mu 1 |
affects metabolic processing affects abundance affects response to substance multiple interactions |
ISO |
GSTM1 protein affects the metabolism of Busulfan GSTM1 gene polymorphism affects the abundance of Busulfan GSTM1 gene polymorphism affects the susceptibility to Busulfan [GSTM1 gene polymorphism co-treated with GSTT1 gene polymorphism] affects the metabolism of Busulfan; [GSTM1 protein co-treated with CYP2C9 protein] results in increased susceptibility to [Busulfan co-treated with Cyclophosphamide] |
CTD |
PMID:8886613 PMID:15142875 PMID:19584821 PMID:20672371 PMID:21215809 PMID:28744217 More...
|
|
NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
affects metabolic processing affects abundance |
ISO |
GSTP1 protein affects the metabolism of Busulfan GSTP1 gene polymorphism affects the abundance of Busulfan |
CTD |
PMID:8886613 PMID:20672371 |
|
NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
|
|
G |
Gstt1 |
glutathione S-transferase theta 1 |
multiple interactions |
ISO |
[GSTM1 gene polymorphism co-treated with GSTT1 gene polymorphism] affects the metabolism of Busulfan |
CTD |
PMID:21215809 |
|
NCBI chr20:12,856,613...12,873,586
Ensembl chr20:12,856,669...12,873,585
|
|
G |
H2ax |
H2A.X variant histone |
increases phosphorylation multiple interactions |
ISO |
Busulfan results in increased phosphorylation of H2AX protein [Clofarabine co-treated with fludarabine co-treated with Busulfan] results in increased expression of H2AX protein |
CTD |
PMID:18339423 PMID:20933509 |
|
NCBI chr 8:44,671,927...44,673,257
Ensembl chr 8:44,671,786...44,673,239
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
increases expression |
ISO |
Busulfan results in increased expression of HIF1A mRNA |
CTD |
PMID:35641671 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions increases expression |
ISO |
4-phenylbutyric acid inhibits the reaction [Busulfan results in increased expression of HSPA5 protein] |
CTD |
PMID:35533795 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Inhba |
inhibin subunit beta A |
multiple interactions increases expression |
ISO |
bisindolylmaleimide I inhibits the reaction [Busulfan results in increased expression of INHBA mRNA]; bisindolylmaleimide I inhibits the reaction [Busulfan results in increased expression of INHBA protein] Busulfan results in increased expression of INHBA mRNA; Busulfan results in increased expression of INHBA protein |
CTD |
PMID:12966370 PMID:22286157 |
|
NCBI chr17:49,091,635...49,111,573
Ensembl chr17:49,095,920...49,108,982
|
|
G |
Kit |
KIT proto-oncogene receptor tyrosine kinase |
decreases expression |
ISO |
Busulfan results in decreased expression of KIT mRNA |
CTD |
PMID:15388331 |
|
NCBI chr14:32,547,459...32,624,694
Ensembl chr14:32,548,877...32,624,652
|
|
G |
Lama1 |
laminin subunit alpha 1 |
affects expression |
ISO |
Busulfan affects the expression of LAMA1 mRNA |
CTD |
PMID:15941629 |
|
NCBI chr 9:107,692,770...107,816,847
Ensembl chr 9:107,692,770...107,817,478
|
|
G |
Lama4 |
laminin subunit alpha 4 |
affects expression |
ISO |
Busulfan affects the expression of LAMA4 mRNA |
CTD |
PMID:15941629 |
|
NCBI chr20:42,392,268...42,533,347
Ensembl chr20:42,392,268...42,533,347
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases activity |
ISO |
Busulfan results in increased activity of MAPK1 protein |
CTD |
PMID:16882877 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases activity |
ISO |
Busulfan results in increased activity of MAPK3 protein |
CTD |
PMID:16882877 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mgst2 |
microsomal glutathione S-transferase 2 |
decreases response to substance |
ISO |
MGST2 protein results in decreased susceptibility to Busulfan |
CTD |
PMID:15779864 |
|
NCBI chr 2:135,679,524...135,715,828
Ensembl chr 2:135,693,557...135,715,828
|
|
G |
Mtf1 |
metal-regulatory transcription factor 1 |
decreases expression |
ISO |
Busulfan results in decreased expression of MTF1 mRNA |
CTD |
PMID:35641671 |
|
NCBI chr 5:137,062,319...137,107,136
Ensembl chr 5:137,062,376...137,107,136
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
multiple interactions |
ISO |
[clofarabine co-treated with fludarabine co-treated with Busulfan] results in decreased expression of MYC protein |
CTD |
PMID:20933509 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Nanos2 |
nanos C2HC-type zinc finger 2 |
decreases expression |
ISO |
Busulfan results in decreased expression of NANOS2 mRNA; Busulfan results in decreased expression of NANOS2 protein |
CTD |
PMID:26524245 |
|
NCBI chr 1:78,635,668...78,637,128
Ensembl chr 1:78,635,668...78,637,128
|
|
G |
Nanos3 |
nanos C2HC-type zinc finger 3 |
decreases expression |
ISO |
Busulfan results in decreased expression of NANOS3 mRNA |
CTD |
PMID:26524245 |
|
NCBI chr19:23,978,465...23,988,933
Ensembl chr19:23,985,504...23,988,932
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
decreases expression increases expression multiple interactions |
ISO |
Busulfan results in decreased expression of NFE2L2 protein Busulfan results in increased expression of NFE2L2 mRNA Deferoxamine inhibits the reaction [Busulfan results in decreased expression of NFE2L2 protein]; ferrostatin-1 inhibits the reaction [Busulfan results in decreased expression of NFE2L2 protein]; sulforaphane inhibits the reaction [Busulfan results in decreased expression of NFE2L2 protein] |
CTD |
PMID:32416107 PMID:35641671 |
|
NCBI chr 3:60,594,239...60,621,785
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
increases expression |
ISO |
Busulfan results in increased expression of NFKB1 mRNA |
CTD |
PMID:35641671 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Npm1 |
nucleophosmin 1 |
multiple interactions |
ISO |
NPM1 gene mutant form results in increased susceptibility to [Busulfan co-treated with Idarubicin] |
CTD |
PMID:20172040 |
|
NCBI chr10:17,741,512...17,751,626
Ensembl chr10:17,739,941...17,751,645
|
|
G |
Ocln |
occludin |
decreases expression multiple interactions |
ISO |
Busulfan results in decreased expression of OCLN mRNA; Busulfan results in decreased expression of OCLN protein 4-phenylbutyric acid inhibits the reaction [Busulfan results in decreased expression of OCLN protein] |
CTD |
PMID:35533795 |
|
NCBI chr 2:31,657,217...31,707,466
Ensembl chr 2:31,657,220...31,764,150
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions increases cleavage |
ISO |
[clofarabine co-treated with fludarabine co-treated with Busulfan] results in increased cleavage of PARP1 protein; [decitabine co-treated with Busulfan] results in increased cleavage of PARP1 protein; pifithrin inhibits the reaction [[decitabine co-treated with Busulfan] results in increased cleavage of PARP1 protein] Busulfan results in increased cleavage of PARP1 protein |
CTD |
PMID:18339423 PMID:19732952 PMID:20933509 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Phb1 |
prohibitin 1 |
affects expression |
ISO |
Busulfan affects the expression of PHB mRNA |
CTD |
PMID:15388331 |
|
NCBI chr10:80,605,268...80,618,043
Ensembl chr10:80,605,251...80,618,042
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
affects expression |
ISO |
Busulfan affects the expression of PPARG mRNA |
CTD |
PMID:35641671 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression multiple interactions |
ISO |
Busulfan results in increased expression of PTGS2 mRNA ferrostatin-1 inhibits the reaction [Busulfan results in increased expression of PTGS2 mRNA] |
CTD |
PMID:12966370 PMID:32416107 |
|
NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Pus7 |
pseudouridine synthase 7 |
increases expression |
ISO |
Busulfan results in increased expression of PUS7 mRNA |
CTD |
PMID:34097952 |
|
NCBI chr 4:11,360,169...11,401,139
Ensembl chr 4:11,360,188...11,401,172
|
|
G |
Rad51 |
RAD51 recombinase |
decreases expression |
ISO |
Busulfan results in decreased expression of RAD51 mRNA |
CTD |
PMID:15388331 |
|
NCBI chr 3:106,099,753...106,125,038
Ensembl chr 3:106,100,381...106,125,035
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
decreases phosphorylation |
ISO |
Busulfan results in decreased phosphorylation of RB1 protein |
CTD |
PMID:15388331 |
|
NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302
|
|
G |
Sat2 |
spermidine/spermine N1-acetyltransferase family member 2 |
increases expression |
ISO |
Busulfan results in increased expression of SAT2 mRNA; Busulfan results in increased expression of SAT2 protein |
CTD |
PMID:28578006 |
|
NCBI chr10:54,340,756...54,343,507
Ensembl chr10:54,340,372...54,343,224
|
|
G |
Serpinc1 |
serpin family C member 1 |
affects expression |
ISO |
Busulfan affects the expression of SERPINC1 protein |
CTD |
PMID:15580502 |
|
NCBI chr13:73,257,208...73,271,476
Ensembl chr13:73,257,179...73,284,293
|
|
G |
Serpine1 |
serpin family E member 1 |
increases expression multiple interactions |
ISO |
Busulfan results in increased expression of SERPINE1 mRNA; Busulfan results in increased expression of SERPINE1 protein 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [Busulfan results in increased expression of SERPINE1 mRNA] |
CTD |
PMID:22286157 |
|
NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657
|
|
G |
Slc40a1 |
solute carrier family 40 member 1 |
decreases expression multiple interactions |
ISO |
Busulfan results in decreased expression of SLC40A1 protein Deferoxamine inhibits the reaction [Busulfan results in decreased expression of SLC40A1 protein]; ferrostatin-1 inhibits the reaction [Busulfan results in decreased expression of SLC40A1 protein]; sulforaphane inhibits the reaction [Busulfan results in decreased expression of SLC40A1 protein] |
CTD |
PMID:32416107 |
|
NCBI chr 9:48,033,526...48,053,876
Ensembl chr 9:48,033,526...48,051,481
|
|
G |
Smc1a |
structural maintenance of chromosomes 1A |
multiple interactions |
ISO |
[clofarabine co-treated with fludarabine co-treated with Busulfan] results in increased phosphorylation of SMC1A protein |
CTD |
PMID:20933509 |
|
NCBI chr X:21,103,323...21,148,053
Ensembl chr X:21,103,282...21,148,056
|
|
G |
Smc3 |
structural maintenance of chromosomes 3 |
multiple interactions |
ISO |
[clofarabine co-treated with fludarabine co-treated with Busulfan] results in increased phosphorylation of SMC3 protein |
CTD |
PMID:20933509 |
|
NCBI chr 1:252,601,422...252,644,522
Ensembl chr 1:252,601,753...252,644,522
|
|
G |
Stat1 |
signal transducer and activator of transcription 1 |
affects expression |
ISO |
Busulfan affects the expression of STAT1 mRNA |
CTD |
PMID:35641671 |
|
NCBI chr 9:49,419,561...49,459,969
Ensembl chr 9:49,419,340...49,588,540
|
|
G |
Stat2 |
signal transducer and activator of transcription 2 |
decreases expression |
ISO |
Busulfan results in decreased expression of STAT2 mRNA |
CTD |
PMID:35641671 |
|
NCBI chr 7:702,565...718,349
Ensembl chr 7:702,495...718,967
|
|
G |
Stra8 |
stimulated by retinoic acid 8 |
decreases expression |
ISO |
Busulfan results in decreased expression of STRA8 mRNA |
CTD |
PMID:15388331 |
|
NCBI chr 4:63,601,443...63,624,777
Ensembl chr 4:63,601,604...63,624,771
|
|
G |
Tf |
transferrin |
multiple interactions increases expression |
ISO |
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [Busulfan results in increased expression of TF mRNA] Busulfan results in increased expression of TF mRNA; Busulfan results in increased expression of TF protein |
CTD |
PMID:12966370 PMID:22286157 |
|
NCBI chr 8:103,789,780...103,816,487
Ensembl chr 8:103,767,995...103,816,511
|
|
G |
Tfpi |
tissue factor pathway inhibitor |
decreases expression |
ISO |
Busulfan results in decreased expression of TFPI mRNA |
CTD |
PMID:22286157 |
|
NCBI chr 3:69,533,156...69,582,547
Ensembl chr 3:69,533,156...69,576,880
|
|
G |
Tfrc |
transferrin receptor |
decreases expression multiple interactions |
ISO |
Busulfan results in decreased expression of TFRC protein Deferoxamine promotes the reaction [Busulfan results in decreased expression of TFRC protein] |
CTD |
PMID:32416107 |
|
NCBI chr11:68,163,413...68,185,257
Ensembl chr11:68,163,413...68,185,257
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
increases expression |
ISO |
Busulfan results in increased expression of TGFB1 mRNA |
CTD |
PMID:22286157 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Thbs1 |
thrombospondin 1 |
increases expression |
ISO |
Busulfan results in increased expression of THBS1 mRNA |
CTD |
PMID:22286157 |
|
NCBI chr 3:105,056,286...105,071,445
Ensembl chr 3:105,056,292...105,071,440
|
|
G |
Tnf |
tumor necrosis factor |
increases expression |
ISO |
Busulfan results in increased expression of TNF mRNA |
CTD |
PMID:22286157 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions increases expression |
ISO |
Busulfan affects the phosphorylation of and affects the activity of TP53 protein Busulfan results in increased expression of TP53 mRNA |
CTD |
PMID:16882877 PMID:35641671 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Txnrd1 |
thioredoxin reductase 1 |
decreases activity |
EXP |
Busulfan results in decreased activity of TXNRD1 protein |
CTD |
PMID:16085187 |
|
NCBI chr 7:20,830,042...20,914,990
Ensembl chr 7:20,830,045...20,907,863
|
|
G |
Xbp1 |
X-box binding protein 1 |
affects expression |
ISO |
Busulfan affects the expression of XBP1 mRNA |
CTD |
PMID:35641671 |
|
NCBI chr14:80,390,629...80,395,713
Ensembl chr14:80,390,643...80,395,693
|
|
G |
Xiap |
X-linked inhibitor of apoptosis |
multiple interactions |
ISO |
[clofarabine co-treated with fludarabine co-treated with Busulfan] results in decreased expression of XIAP protein |
CTD |
PMID:20933509 |
|
NCBI chr X:120,890,537...120,938,413
Ensembl chr X:120,897,907...120,934,700
|
|
G |
Zbtb16 |
zinc finger and BTB domain containing 16 |
increases expression |
ISO |
Busulfan results in increased expression of ZBTB16 mRNA |
CTD |
PMID:26524245 |
|
NCBI chr 8:48,989,376...49,177,011
Ensembl chr 8:48,994,566...49,177,011
|
|
|
G |
Chrna2 |
cholinergic receptor nicotinic alpha 2 subunit |
multiple interactions |
ISO |
2-butanol affects the reaction [Acetylcholine promotes the reaction [[CHRNA2 protein binds to CHRNB4 protein] which results in increased transport of Barium]] |
CTD |
PMID:11821649 |
|
NCBI chr15:40,342,317...40,358,601
Ensembl chr15:40,342,317...40,358,601
|
|
G |
Chrnb4 |
cholinergic receptor nicotinic beta 4 subunit |
multiple interactions |
ISO |
2-butanol affects the reaction [Acetylcholine promotes the reaction [[CHRNA2 protein binds to CHRNB4 protein] which results in increased transport of Barium]] |
CTD |
PMID:11821649 |
|
NCBI chr 8:55,418,379...55,436,967
Ensembl chr 8:55,418,313...55,437,027
|
|
G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
multiple interactions |
EXP |
2-butanol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EIF4EBP1 protein] |
CTD |
PMID:14769825 |
|
NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984
|
|
G |
Gh1 |
growth hormone 1 |
affects folding |
ISO |
2-butanol affects the folding of GH1 protein |
CTD |
PMID:11064379 |
|
NCBI chr10:91,228,102...91,230,079
Ensembl chr10:91,228,103...91,230,078
|
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression |
ISO |
butane results in increased expression of BAX mRNA |
CTD |
PMID:33064461 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Fn1 |
fibronectin 1 |
decreases expression |
ISO |
butane results in decreased expression of FN1 mRNA |
CTD |
PMID:33064461 |
|
NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678
|
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
increases activity increases expression |
EXP |
1,3-butylene glycol results in increased activity of CYP2E1 protein 1,3-butylene glycol results in increased expression of CYP2E1 protein |
CTD |
PMID:2919394 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
|
G |
Akr1b1 |
aldo-keto reductase family 1 member B1 |
multiple interactions |
ISO |
[AKR1B1 protein results in increased reduction of Acetoin] which results in increased chemical synthesis of 2,3-butylene glycol |
CTD |
PMID:23295224 |
|
NCBI chr 4:62,932,033...62,946,126
Ensembl chr 4:62,932,031...62,946,157
|
|
G |
Akr1b10 |
aldo-keto reductase family 1 member B10 |
multiple interactions |
ISO |
[AKR1B10 protein results in increased reduction of Acetoin] which results in increased chemical synthesis of 2,3-butylene glycol |
CTD |
PMID:23295224 |
|
NCBI chr 4:63,038,459...63,060,336
Ensembl chr 4:63,040,169...63,053,852
|
|
G |
Aldh2 |
aldehyde dehydrogenase 2 family member |
increases metabolic processing |
ISO |
ALDH2 protein results in increased metabolism of 2,3-butylene glycol |
CTD |
PMID:10064379 |
|
NCBI chr12:34,949,549...34,982,527
Ensembl chr12:34,901,219...34,982,521
|
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
multiple interactions |
EXP |
[Oxygen deficiency co-treated with Carbon Dioxide] results in decreased expression of BDNF protein; ifenprodil inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in decreased expression of BDNF protein]; Lovastatin inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in decreased expression of BDNF protein] |
CTD |
PMID:24718106 |
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Calca |
calcitonin-related polypeptide alpha |
multiple interactions increases secretion |
EXP |
Carbon Dioxide inhibits the reaction [Capsaicin results in increased secretion of CALCA protein]; Carbon Dioxide inhibits the reaction [Potassium Chloride results in increased secretion of CALCA protein]; Carbon Dioxide inhibits the reaction [S-Nitroso-N-Acetylpenicillamine results in increased secretion of CALCA protein] Carbon Dioxide results in increased secretion of CALCA protein |
CTD |
PMID:18052948 |
|
NCBI chr 1:168,878,212...168,883,176
Ensembl chr 1:168,878,214...168,883,105
|
|
G |
Camk2b |
calcium/calmodulin-dependent protein kinase II beta |
multiple interactions |
EXP |
[Oxygen deficiency co-treated with Carbon Dioxide] results in increased expression of CAMK2B protein; ifenprodil inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in increased expression of CAMK2B protein]; Lovastatin inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in increased expression of CAMK2B protein] |
CTD |
PMID:24718106 |
|
NCBI chr14:80,845,206...80,934,172
Ensembl chr14:80,845,238...80,933,994
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions |
EXP |
[Oxygen deficiency co-treated with Carbon Dioxide] results in decreased phosphorylation of CREB1 protein; ifenprodil inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in decreased phosphorylation of CREB1 protein]; Lovastatin inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in decreased phosphorylation of CREB1 protein] |
CTD |
PMID:24718106 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Crh |
corticotropin releasing hormone |
increases response to substance |
ISO |
CRH protein results in increased susceptibility to Carbon Dioxide |
CTD |
PMID:8957205 |
|
NCBI chr 2:102,143,055...102,144,919
Ensembl chr 2:102,143,055...102,144,919
|
|
G |
Dlg3 |
discs large MAGUK scaffold protein 3 |
multiple interactions |
EXP |
[Oxygen deficiency co-treated with Carbon Dioxide] results in increased expression of DLG3 protein; ifenprodil inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in increased expression of DLG3 protein]; Lovastatin inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in increased expression of DLG3 protein] |
CTD |
PMID:24718106 |
|
NCBI chr X:65,859,653...65,911,887
Ensembl chr X:65,860,172...65,910,322
|
|
G |
Grin2b |
glutamate ionotropic receptor NMDA type subunit 2B |
multiple interactions |
EXP |
[Oxygen deficiency co-treated with Carbon Dioxide] results in increased expression of GRIN2B protein; ifenprodil inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in increased expression of GRIN2B protein]; Lovastatin inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in increased expression of GRIN2B protein] |
CTD |
PMID:24718106 |
|
NCBI chr 4:168,580,824...169,044,110
Ensembl chr 4:168,599,546...169,042,279
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
EXP |
[Oxygen deficiency co-treated with Carbon Dioxide] results in decreased phosphorylation of MAPK1 protein; [Oxygen deficiency co-treated with Carbon Dioxide] results in increased expression of MAPK1 mRNA; [Oxygen deficiency co-treated with Carbon Dioxide] results in increased phosphorylation of MAPK1 protein; ifenprodil inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in decreased phosphorylation of MAPK1 protein]; Lovastatin inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in decreased phosphorylation of MAPK1 protein]; notoginsenoside R1 inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in increased expression of MAPK1 mRNA]; notoginsenoside R1 inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:24718106 PMID:25004876 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
EXP |
[Oxygen deficiency co-treated with Carbon Dioxide] results in decreased phosphorylation of MAPK3 protein; [Oxygen deficiency co-treated with Carbon Dioxide] results in increased expression of MAPK3 mRNA; [Oxygen deficiency co-treated with Carbon Dioxide] results in increased phosphorylation of MAPK3 protein; ifenprodil inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in decreased phosphorylation of MAPK3 protein]; Lovastatin inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in decreased phosphorylation of MAPK3 protein]; notoginsenoside R1 inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in increased expression of MAPK3 mRNA]; notoginsenoside R1 inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:24718106 PMID:25004876 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mir29a |
microRNA 29a |
multiple interactions |
ISO |
[[Vehicle Emissions results in increased abundance of Air Pollutants] which results in increased abundance of Carbon Dioxide] which results in increased expression of MIR29A mRNA |
CTD |
PMID:29980036 |
|
NCBI chr 4:59,650,608...59,650,695
|
|
G |
Neil1 |
nei-like DNA glycosylase 1 |
affects abundance |
ISO |
NEIL1 affects the abundance of Carbon Dioxide |
CTD |
PMID:21285402 |
|
NCBI chr 8:57,550,142...57,556,884
Ensembl chr 8:57,550,147...57,556,258
|
|
G |
Ngb |
neuroglobin |
affects binding |
ISO |
Carbon Dioxide binds to [Heme binds to NGB protein] |
CTD |
PMID:16684569 |
|
NCBI chr 6:106,744,378...106,749,830
Ensembl chr 6:106,744,378...106,749,830
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO |
PPARA protein promotes the reaction [[GW 7647 results in increased oxidation of Palmitic Acid] which results in increased abundance of Carbon Dioxide] |
CTD |
PMID:21324916 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Rapgef3 |
Rap guanine nucleotide exchange factor 3 |
multiple interactions |
ISO |
[RAPGEF3 protein affects the susceptibility to Dietary Fats] which affects the chemical synthesis of Carbon Dioxide |
CTD |
PMID:27381457 |
|
NCBI chr 7:128,875,772...128,898,203
Ensembl chr 7:128,875,773...128,898,521
|
|
G |
Slc9a1 |
solute carrier family 9 member A1 |
affects response to substance |
EXP |
SLC9A1 protein affects the susceptibility to Carbon Dioxide |
CTD |
PMID:16831598 |
|
NCBI chr 5:145,576,341...145,629,630
Ensembl chr 5:145,576,334...145,629,624
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions |
ISO |
[[[Bicarbonates co-treated with Carbon Dioxide] promotes the reaction [SOD1 protein binds to peroxycarbonic acid]] which results in increased reduction of peroxycarbonic acid] which results in increased chemical synthesis of Carbonates; [[Bicarbonates co-treated with Carbon Dioxide] promotes the reaction [SOD1 protein binds to peroxycarbonic acid]] which results in increased reduction of peroxycarbonic acid; [[SOD1 protein results in increased metabolism of Hydrogen Peroxide] results in increased oxidation of [Bicarbonates co-treated with Carbon Dioxide]] which results in increased chemical synthesis of Carbonates; [Bicarbonates co-treated with Carbon Dioxide] promotes the reaction [SOD1 protein binds to peroxycarbonic acid]; [Bicarbonates co-treated with Carbon Dioxide] promotes the reaction [SOD1 protein results in increased metabolism of Hydrogen Peroxide]; [SOD1 protein results in increased metabolism of Hydrogen Peroxide] results in increased oxidation of [Bicarbonates co-treated with Carbon Dioxide] |
CTD |
PMID:19243126 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Syncrip |
synaptotagmin binding, cytoplasmic RNA interacting protein |
multiple interactions |
ISO |
[[Vehicle Emissions results in increased abundance of Air Pollutants] which results in increased abundance of Carbon Dioxide] which affects the expression of SYNCRIP mRNA |
CTD |
PMID:29980036 |
|
NCBI chr 8:89,402,487...89,435,517
Ensembl chr 8:89,402,866...89,435,515
|
|
G |
Syngap1 |
synaptic Ras GTPase activating protein 1 |
multiple interactions |
EXP |
[Oxygen deficiency co-treated with Carbon Dioxide] results in increased expression of SYNGAP1 protein; ifenprodil inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in increased expression of SYNGAP1 protein]; Lovastatin inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in increased expression of SYNGAP1 protein] |
CTD |
PMID:24718106 |
|
NCBI chr20:5,026,366...5,056,659
Ensembl chr20:5,026,364...5,056,672
|
|
G |
Tpi1 |
triosephosphate isomerase 1 |
increases expression |
EXP |
Carbon Dioxide results in increased expression of TPI1 mRNA |
CTD |
PMID:14762718 |
|
NCBI chr 4:157,615,283...157,618,813
Ensembl chr 4:157,615,386...157,619,541
|
|
G |
Trh |
thyrotropin releasing hormone |
increases response to substance |
ISO |
TRH protein results in increased susceptibility to Carbon Dioxide |
CTD |
PMID:8957205 |
|
NCBI chr 4:124,742,111...124,777,094
Ensembl chr 4:124,742,111...124,744,637
|
|
G |
Trpa1 |
transient receptor potential cation channel, subfamily A, member 1 |
increases activity |
EXP |
Carbon Dioxide results in increased activity of TRPA1 protein |
CTD |
PMID:20881114 |
|
NCBI chr 5:4,379,999...4,433,243
Ensembl chr 5:4,379,999...4,433,570
|
|
G |
Trpv1 |
transient receptor potential cation channel, subfamily V, member 1 |
affects response to substance |
EXP |
TRPV1 protein affects the susceptibility to Carbon Dioxide |
CTD |
PMID:16831598 |
|
NCBI chr10:57,851,428...57,876,513
Ensembl chr10:57,851,428...57,876,513
|
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
ISO |
1,3-dihydro-1-(1-((4-(6-phenyl-1H-imidazo(4,5-g)quinoxalin-7-yl)phenyl)methyl)-4-piperidinyl)-2H-benzimidazol-2-one promotes the reaction [N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [polyhexamethyleneguanidine results in increased expression of ACTA2 protein]]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [polyhexamethyleneguanidine results in increased expression of ACTA2 protein]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester promotes the reaction [1,3-dihydro-1-(1-((4-(6-phenyl-1H-imidazo(4,5-g)quinoxalin-7-yl)phenyl)methyl)-4-piperidinyl)-2H-benzimidazol-2-one inhibits the reaction [polyhexamethyleneguanidine results in increased expression of ACTA2 protein]] |
CTD |
PMID:31348943 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
1,3-dihydro-1-(1-((4-(6-phenyl-1H-imidazo(4,5-g)quinoxalin-7-yl)phenyl)methyl)-4-piperidinyl)-2H-benzimidazol-2-one promotes the reaction [N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [polyhexamethyleneguanidine results in increased phosphorylation of AKT1 protein]]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [polyhexamethyleneguanidine results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:31348943 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Tunicamycin results in increased secretion of APP protein modified form] |
CTD |
PMID:22115781 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression multiple interactions |
EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in increased expression of BAX protein N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [[Polyribonucleotides results in decreased expression of MIR141 mRNA] inhibits the reaction [Palmitic Acid results in increased expression of BAX protein]] |
CTD |
PMID:21209419 PMID:34897970 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression multiple interactions |
EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of BCL2 protein N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [[Polyribonucleotides results in decreased expression of MIR141 mRNA] inhibits the reaction [Palmitic Acid results in decreased expression of BCL2 protein]] |
CTD |
PMID:21209419 PMID:34897970 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bmp6 |
bone morphogenetic protein 6 |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [BMP6 protein results in increased expression of KRT1 mRNA]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [BMP6 protein results in increased expression of KRT10 mRNA] |
CTD |
PMID:23566955 |
|
NCBI chr17:26,318,121...26,469,034
Ensembl chr17:26,318,569...26,470,365
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [[Polyribonucleotides results in decreased expression of MIR141 mRNA] inhibits the reaction [Palmitic Acid results in increased expression of CASP3 protein modified form]]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in increased expression of and results in increased activity of CASP3 protein |
CTD |
PMID:21209419 PMID:34897970 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [[Polyribonucleotides results in decreased expression of MIR141 mRNA] inhibits the reaction [Palmitic Acid results in increased expression of CASP9 protein modified form]] |
CTD |
PMID:34897970 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [baicalein results in increased expression of CCND1 mRNA]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [baicalin results in increased expression of CCND1 mRNA] |
CTD |
PMID:19160421 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Cdh1 |
cadherin 1 |
multiple interactions |
ISO |
[N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester co-treated with 1,3-dihydro-1-(1-((4-(6-phenyl-1H-imidazo(4,5-g)quinoxalin-7-yl)phenyl)methyl)-4-piperidinyl)-2H-benzimidazol-2-one] inhibits the reaction [polyhexamethyleneguanidine results in decreased expression of CDH1 protein]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Cadmium Chloride results in increased secretion of CDH1 protein]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Cadmium results in increased cleavage of CDH1 protein] |
CTD |
PMID:18791180 PMID:31348943 |
|
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Cdh2 |
cadherin 2 |
multiple interactions |
EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Cadmium Chloride results in increased cleavage of CDH2 protein] |
CTD |
PMID:23876460 |
|
NCBI chr18:7,776,704...7,990,934
Ensembl chr18:7,776,704...7,990,167
|
|
G |
Csf1 |
colony stimulating factor 1 |
multiple interactions |
EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of CSF1 mRNA] |
CTD |
PMID:24223152 |
|
NCBI chr 2:195,377,215...195,396,608
Ensembl chr 2:195,377,215...195,411,704
|
|
G |
Eno2 |
enolase 2 |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester promotes the reaction [rhodioloside results in increased expression of ENO2 mRNA] |
CTD |
PMID:24929042 |
|
NCBI chr 4:157,572,085...157,580,971
Ensembl chr 4:157,572,088...157,580,980
|
|
G |
Flt1 |
Fms related receptor tyrosine kinase 1 |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester promotes the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of FLT1 protein] |
CTD |
PMID:21843347 |
|
NCBI chr12:7,296,899...7,468,626
Ensembl chr12:7,297,292...7,468,626
|
|
G |
Foxo3 |
forkhead box O3 |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester promotes the reaction [Hydrogen Peroxide results in increased expression of FOXO3 protein] |
CTD |
PMID:25108166 |
|
NCBI chr20:45,669,708...45,764,606
Ensembl chr20:45,672,995...45,764,561
|
|
G |
Hes1 |
hes family bHLH transcription factor 1 |
multiple interactions decreases expression |
ISO EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [baicalein results in increased expression of HES1 mRNA]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [baicalin results in increased expression of HES1 mRNA]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Hydrogen Peroxide results in increased expression of HES1 protein] N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of HES1 mRNA]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [tetrabromobisphenol A results in increased expression of HES1 mRNA] N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of HES1 protein] N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of HES1 protein |
CTD |
PMID:19160421 PMID:24223152 PMID:25005833 PMID:25108166 PMID:32041402 |
|
NCBI chr11:70,705,763...70,708,176
Ensembl chr11:70,705,764...70,708,192
|
|
G |
Hey1 |
hes-related family bHLH transcription factor with YRPW motif 1 |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [baicalein results in increased expression of HEY1 mRNA]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [baicalin results in increased expression of HEY1 mRNA] |
CTD |
PMID:19160421 |
|
NCBI chr 2:93,096,706...93,100,316
Ensembl chr 2:93,095,498...93,100,312
|
|
G |
Hey2 |
hes-related family bHLH transcription factor with YRPW motif 2 |
multiple interactions |
ISO EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [baicalein results in increased expression of HEY2 mRNA]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [baicalin results in increased expression of HEY2 mRNA]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Niclosamide results in increased expression of HEY2 mRNA] N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [tetrabromobisphenol A results in increased expression of HEY2 mRNA] |
CTD |
PMID:19160421 PMID:32041402 |
|
NCBI chr 1:26,822,131...26,832,218
Ensembl chr 1:26,822,131...26,832,218
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester promotes the reaction [Hydrogen Peroxide results in increased expression of HIF1A protein] |
CTD |
PMID:25108166 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hmgb1 |
high mobility group box 1 |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of HMGB1 protein] |
CTD |
PMID:21843347 |
|
NCBI chr12:5,973,062...5,978,565
Ensembl chr12:5,901,586...5,978,565
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of IL10 mRNA] |
CTD |
PMID:24223152 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of IL1B protein]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of IL1B protein] N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of IL1B mRNA] |
CTD |
PMID:21843347 PMID:24223152 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of IL6 mRNA] N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of IL6 protein] |
CTD |
PMID:21843347 PMID:24223152 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Itgam |
integrin subunit alpha M |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [4-amino-2-trifluoromethyl-phenyl retinate results in increased expression of ITGAM protein] |
CTD |
PMID:28130038 |
|
NCBI chr 1:182,659,047...182,709,495
Ensembl chr 1:182,659,000...182,709,503
|
|
G |
Ivl |
involucrin |
decreases expression |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of IVL mRNA; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of IVL protein |
CTD |
PMID:18633435 |
|
NCBI chr 2:178,146,694...178,160,807
Ensembl chr 2:178,147,061...178,149,100
|
|
G |
Jag1 |
jagged canonical Notch ligand 1 |
decreases expression |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of JAG1 mRNA; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of JAG1 protein |
CTD |
PMID:18633435 |
|
NCBI chr 3:124,406,794...124,442,220
Ensembl chr 3:124,406,794...124,442,209
|
|
G |
Krt1 |
keratin 1 |
multiple interactions decreases expression |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [BMP6 protein results in increased expression of KRT1 mRNA]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [U 0126 results in increased expression of KRT1 mRNA] N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of KRT1 mRNA |
CTD |
PMID:18633435 PMID:23566955 |
|
NCBI chr 7:132,976,618...132,981,844
Ensembl chr 7:132,976,620...132,981,844
|
|
G |
Krt10 |
keratin 10 |
multiple interactions decreases expression |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [BMP6 protein results in increased expression of KRT10 mRNA]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [U 0126 results in increased expression of KRT10 mRNA] N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of KRT10 mRNA; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of KRT10 protein |
CTD |
PMID:18633435 PMID:23566955 |
|
NCBI chr10:84,338,695...84,343,279
Ensembl chr10:84,338,706...84,343,701
|
|
G |
Lgr5 |
leucine rich repeat containing G protein coupled receptor 5 |
multiple interactions |
EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [tetrabromobisphenol A results in increased expression of LGR5 mRNA] |
CTD |
PMID:32041402 |
|
NCBI chr 7:51,087,059...51,221,882
Ensembl chr 7:51,088,239...51,222,446
|
|
G |
Map2 |
microtubule-associated protein 2 |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester promotes the reaction [rhodioloside results in increased expression of MAP2 mRNA] |
CTD |
PMID:24929042 |
|
NCBI chr 9:67,723,422...67,981,886
Ensembl chr 9:67,723,371...67,979,809
|
|
G |
Mdm2 |
MDM2 proto-oncogene |
multiple interactions increases expression |
ISO |
Hydrogen Peroxide inhibits the reaction [N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in increased expression of MDM2 protein] |
CTD |
PMID:25005833 |
|
NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915
|
|
G |
Mir141 |
microRNA 141 |
multiple interactions |
EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [[Polyribonucleotides results in decreased expression of MIR141 mRNA] inhibits the reaction [Palmitic Acid results in decreased expression of BCL2 protein]]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [[Polyribonucleotides results in decreased expression of MIR141 mRNA] inhibits the reaction [Palmitic Acid results in increased expression of BAX protein]]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [[Polyribonucleotides results in decreased expression of MIR141 mRNA] inhibits the reaction [Palmitic Acid results in increased expression of CASP3 protein modified form]]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [[Polyribonucleotides results in decreased expression of MIR141 mRNA] inhibits the reaction [Palmitic Acid results in increased expression of CASP9 protein modified form]] |
CTD |
PMID:34897970 |
|
NCBI chr 4:157,523,239...157,523,332
Ensembl chr 4:157,523,239...157,523,332
|
|
G |
Myd88 |
MYD88, innate immune signal transduction adaptor |
multiple interactions |
ISO EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of MYD88 protein] N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of MYD88 mRNA] |
CTD |
PMID:24223152 |
|
NCBI chr 8:119,074,439...119,078,508
Ensembl chr 8:119,074,437...119,079,415
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of NOS2 protein] N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of NOS2 mRNA] |
CTD |
PMID:24223152 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Notch1 |
notch receptor 1 |
multiple interactions decreases expression |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [4-amino-2-trifluoromethyl-phenyl retinate results in increased expression of NOTCH1 protein]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Cadmium Chloride results in increased cleavage of NOTCH1 protein]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Hydrogen Peroxide results in increased cleavage of NOTCH1 protein]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [phenethyl isothiocyanate results in increased cleavage of and results in increased activity of NOTCH1 protein]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [polyhexamethyleneguanidine results in increased cleavage of NOTCH1 protein]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester promotes the reaction [1,3-dihydro-1-(1-((4-(6-phenyl-1H-imidazo(4,5-g)quinoxalin-7-yl)phenyl)methyl)-4-piperidinyl)-2H-benzimidazol-2-one inhibits the reaction [polyhexamethyleneguanidine results in increased cleavage of NOTCH1 protein]]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased cleavage of and results in decreased activity of NOTCH1 protein N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency affects the localization of NOTCH1 protein modified form]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Tunicamycin results in increased cleavage of NOTCH1 protein]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester promotes the reaction [Oxygen deficiency results in increased expression of NOTCH1 protein] N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of NOTCH1 protein modified form |
CTD |
PMID:18633435 PMID:22039516 PMID:22115781 PMID:24223152 PMID:25108166 PMID:25118938 PMID:28130038 PMID:31348943 More...
|
|
NCBI chr 3:9,277,955...9,323,531
Ensembl chr 3:9,278,086...9,323,531
|
|
G |
Notch2 |
notch receptor 2 |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased cleavage of and results in decreased activity of NOTCH2 protein |
CTD |
PMID:22039516 |
|
NCBI chr 2:185,610,594...185,744,088
Ensembl chr 2:185,610,589...185,744,088
|
|
G |
Numb |
NUMB, endocytic adaptor protein |
increases expression |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in increased expression of NUMB protein |
CTD |
PMID:25005833 |
|
NCBI chr 6:103,431,400...103,553,422
Ensembl chr 6:103,431,400...103,553,354
|
|
G |
Pml |
PML nuclear body scaffold |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [4-amino-2-trifluoromethyl-phenyl retinate results in increased degradation of [PML protein mutant form binds to RARA protein mutant form]] |
CTD |
PMID:28130038 |
|
NCBI chr 8:58,627,347...58,661,927
Ensembl chr 8:58,628,837...58,658,971
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Cadmium results in increased expression of PTGS2 mRNA] |
CTD |
PMID:18791180 |
|
NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rara |
retinoic acid receptor, alpha |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [4-amino-2-trifluoromethyl-phenyl retinate results in increased degradation of [PML protein mutant form binds to RARA protein mutant form]] |
CTD |
PMID:28130038 |
|
NCBI chr10:83,883,490...83,928,932
Ensembl chr10:83,893,384...83,928,142
|
|
G |
Rbpj |
recombination signal binding protein for immunoglobulin kappa J region |
multiple interactions increases expression |
EXP ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of RBPJ mRNA] N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in increased expression of RBPJ protein N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Cycloheximide results in decreased expression of RBPJ protein] |
CTD |
PMID:22302987 PMID:24223152 |
|
NCBI chr14:57,338,493...57,523,330
Ensembl chr14:57,338,507...57,523,353
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency affects the localization of RELA protein modified form]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of RELA protein] |
CTD |
PMID:24223152 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of TGFB1 mRNA] |
CTD |
PMID:24223152 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions |
EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of TLR4 mRNA] |
CTD |
PMID:24223152 |
|
NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of TNF protein] N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of TNF mRNA] |
CTD |
PMID:24223152 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tp53 |
tumor protein p53 |
decreases expression multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of TP53 protein Hydrogen Peroxide inhibits the reaction [N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of TP53 protein] |
CTD |
PMID:25005833 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Traf6 |
TNF receptor associated factor 6 |
multiple interactions |
ISO EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of TRAF6 protein] N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of TRAF6 mRNA] |
CTD |
PMID:24223152 |
|
NCBI chr 3:87,963,517...87,988,316
Ensembl chr 3:87,963,514...87,983,507
|
|
G |
Tubb3 |
tubulin, beta 3 class III |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester promotes the reaction [rhodioloside results in increased expression of TUBB3 mRNA] |
CTD |
PMID:24929042 |
|
NCBI chr19:51,457,187...51,466,243
Ensembl chr19:51,457,184...51,466,243
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of VEGFA protein] |
CTD |
PMID:21843347 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Vil1 |
villin 1 |
multiple interactions |
EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [tetrabromobisphenol A results in increased expression of VIL1 mRNA] |
CTD |
PMID:32041402 |
|
NCBI chr 9:75,991,141...76,018,860
Ensembl chr 9:75,991,141...76,018,858
|
|
|
G |
A4galt |
alpha 1,4-galactosyltransferase (P blood group) |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of A4GALT mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 7:114,368,525...114,392,872
Ensembl chr 7:114,368,276...114,396,071
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ABCG2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Adamts1 |
ADAM metallopeptidase with thrombospondin type 1 motif, 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of ADAMTS1 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of ADAMTS1 mRNA] |
CTD |
PMID:33316053 |
|
NCBI chr11:24,932,227...24,941,068
Ensembl chr11:24,931,761...24,941,103
|
|
G |
Ak5 |
adenylate kinase 5 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of AK5 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 2:241,397,297...241,581,483
Ensembl chr 2:241,397,297...241,581,458
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of ALDH1A1 mRNA |
CTD |
PMID:30768133 |
|
NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961
|
|
G |
Aldh2 |
aldehyde dehydrogenase 2 family member |
decreases expression |
EXP |
diisobutyl phthalate results in decreased expression of ALDH2 mRNA |
CTD |
PMID:33983380 |
|
NCBI chr12:34,949,549...34,982,527
Ensembl chr12:34,901,219...34,982,521
|
|
G |
Aldoc |
aldolase, fructose-bisphosphate C |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ALDOC mRNA |
CTD |
PMID:31199487 |
|
NCBI chr10:63,217,477...63,221,066
Ensembl chr10:63,217,451...63,221,066
|
|
G |
Amhr2 |
anti-Mullerian hormone receptor type 2 |
increases expression |
EXP |
diisobutyl phthalate results in increased expression of AMHR2 mRNA |
CTD |
PMID:22112501 |
|
NCBI chr 7:133,579,152...133,588,874
Ensembl chr 7:133,579,393...133,588,258
|
|
G |
Ar |
androgen receptor |
affects binding multiple interactions |
EXP ISO |
diisobutyl phthalate binds to AR protein diisobutyl phthalate inhibits the reaction [Dihydrotestosterone binds to and results in increased activity of AR protein]; diisobutyl phthalate inhibits the reaction [Dihydrotestosterone results in increased activity of AR protein] |
CTD |
PMID:14565775 PMID:15840436 PMID:28571686 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Arnt2 |
aryl hydrocarbon receptor nuclear translocator 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ARNT2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:138,236,235...138,392,868
Ensembl chr 1:138,189,940...138,393,153
|
|
G |
Astn1 |
astrotactin 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ASTN1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr13:70,537,423...70,855,440
Ensembl chr13:70,537,703...70,855,440
|
|
G |
Astn2 |
astrotactin 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ASTN2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 5:78,758,142...79,744,021
Ensembl chr 5:78,758,142...79,748,273
|
|
G |
Atp1a3 |
ATPase Na+/K+ transporting subunit alpha 3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ATP1A3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:80,572,790...80,601,936
Ensembl chr 1:80,572,796...80,601,918
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of BAX mRNA |
CTD |
PMID:28013214 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcat1 |
branched chain amino acid transaminase 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of BCAT1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 4:177,964,834...178,046,573
Ensembl chr 4:177,964,834...178,046,597
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of BCL2 mRNA |
CTD |
PMID:28013214 PMID:35762964 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bend6 |
BEN domain containing 6 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of BEND6 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 9:36,081,033...36,135,309
Ensembl chr 9:36,081,484...36,135,228
|
|
G |
Bpgm |
bisphosphoglycerate mutase |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of BPGM mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 4:63,139,730...63,168,581
Ensembl chr 4:63,140,018...63,168,581
|
|
G |
Cacng7 |
calcium voltage-gated channel auxiliary subunit gamma 7 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CACNG7 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:65,800,820...65,831,165
Ensembl chr 1:65,800,355...65,831,006
|
|
G |
Cadm3 |
cell adhesion molecule 3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CADM3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr13:85,786,482...85,817,412
Ensembl chr13:85,786,483...85,817,749
|
|
G |
Cadps |
calcium dependent secretion activator |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CADPS mRNA |
CTD |
PMID:31199487 |
|
NCBI chr15:12,289,803...12,742,786
Ensembl chr15:12,290,262...12,742,779
|
|
G |
Camk4 |
calcium/calmodulin-dependent protein kinase IV |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CAMK4 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr18:24,582,988...24,811,918
Ensembl chr18:24,585,269...24,802,487
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CASP8 mRNA |
CTD |
PMID:28013214 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CAT mRNA |
CTD |
PMID:28013214 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccnd2 |
cyclin D2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CCND2 mRNA |
CTD |
PMID:28013214 |
|
NCBI chr 4:159,966,883...159,989,261
Ensembl chr 4:159,962,363...159,989,495
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of CDK4 mRNA |
CTD |
PMID:35762964 |
|
NCBI chr 7:62,885,647...62,889,562
Ensembl chr 7:62,883,105...62,942,403
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions |
ISO EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of CDKN1A mRNA] [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CDKN1A mRNA |
CTD |
PMID:33316053 PMID:35762964 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of CDKN2A mRNA |
CTD |
PMID:28013214 |
|
NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149
|
|
G |
Celsr3 |
cadherin, EGF LAG seven-pass G-type receptor 3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CELSR3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:109,530,597...109,558,360
Ensembl chr 8:109,530,641...109,558,354
|
|
G |
Cga |
glycoprotein hormones, alpha polypeptide |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of ADAMTS1 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of EDN2 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of MMP9 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of PGR mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of PLAT mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of ADAMTS1 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of CDKN1A mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of IL6 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of PTGS2 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of SERPINB2 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of SERPINE1 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of TIMP1 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of WNT4 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] promotes the reaction [CGA protein results in increased expression of MMP14 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] promotes the reaction [CGA protein results in increased expression of MMP16 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] promotes the reaction [CGA protein results in increased expression of SLCO2A1 mRNA] |
CTD |
PMID:33316053 |
|
NCBI chr 5:49,486,915...49,499,192
Ensembl chr 5:49,487,068...49,499,191
|
|
G |
Chga |
chromogranin A |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CHGA mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 6:121,696,051...121,707,399
Ensembl chr 6:121,696,051...121,707,398
|
|
G |
Chgb |
chromogranin B |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CHGB mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 3:120,043,824...120,057,169
Ensembl chr 3:120,043,738...120,057,166
|
|
G |
Cited1 |
Cbp/p300-interacting transactivator with Glu/Asp-rich carboxy-terminal domain 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CITED1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr X:67,350,376...67,355,072
Ensembl chr X:67,350,373...67,355,162
|
|
G |
Clstn3 |
calsyntenin 3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CLSTN3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 4:157,331,494...157,364,769
Ensembl chr 4:157,331,494...157,364,769
|
|
G |
Cntnap1 |
contactin associated protein 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CNTNAP1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr10:86,109,850...86,125,612
Ensembl chr10:86,111,643...86,125,611
|
|
G |
Crmp1 |
collapsin response mediator protein 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CRMP1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr14:73,509,933...73,556,192
Ensembl chr14:73,509,933...73,556,177
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
decreases expression multiple interactions |
EXP ISO |
diisobutyl phthalate results in decreased expression of CYP11A1 mRNA; diisobutyl phthalate results in decreased expression of CYP11A1 protein [diethyl phthalate co-treated with diisobutyl phthalate] results in decreased expression of CYP11A1 mRNA [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CYP11A1 mRNA; [Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diethyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in decreased expression of CYP11A1 mRNA; [Diethylhexyl Phthalate co-treated with diethyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate] results in decreased expression of CYP11A1 mRNA |
CTD |
PMID:16458459 PMID:21633115 PMID:22112501 PMID:28013214 PMID:30802670 PMID:33983380 PMID:34597818 More...
|
|
NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338
|
|
G |
Cyp11b2 |
cytochrome P450, family 11, subfamily b, polypeptide 2 |
multiple interactions decreases expression |
EXP |
[diethyl phthalate co-treated with diisobutyl phthalate] results in decreased expression of CYP11B1 mRNA diisobutyl phthalate results in decreased expression of CYP11B1 mRNA |
CTD |
PMID:22112501 PMID:33983380 |
|
NCBI chr 7:106,838,590...106,845,004
Ensembl chr 7:106,838,590...106,845,004
|
|
G |
Cyp11b3 |
cytochrome P450, family 11, subfamily b, polypeptide 3 |
decreases expression multiple interactions |
EXP |
diisobutyl phthalate results in decreased expression of CYP11B2 mRNA [diethyl phthalate co-treated with diisobutyl phthalate] results in decreased expression of CYP11B2 mRNA |
CTD |
PMID:33983380 |
|
NCBI chr 7:106,808,559...106,814,048
Ensembl chr 7:106,808,559...106,814,048
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
decreases expression multiple interactions |
EXP ISO |
diisobutyl phthalate results in decreased expression of CYP17A1 mRNA [diethyl phthalate co-treated with diisobutyl phthalate] results in decreased expression of CYP17A1 mRNA [Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diethyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in decreased expression of CYP17A1 mRNA |
CTD |
PMID:22112501 PMID:28655647 PMID:30802670 PMID:33983380 |
|
NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CYP19A1 mRNA; [Diethylhexyl Phthalate co-treated with diethyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate] results in decreased expression of CYP19A1 mRNA |
CTD |
PMID:28013214 PMID:34597818 |
|
NCBI chr 8:54,553,165...54,580,758
Ensembl chr 8:54,553,165...54,580,758
|
|
G |
Cyp51 |
cytochrome P450, family 51 |
decreases expression |
EXP |
diisobutyl phthalate results in decreased expression of CYP51 mRNA |
CTD |
PMID:33983380 |
|
NCBI chr 4:30,036,956...30,055,410
Ensembl chr 4:30,036,865...30,055,410
|
|
G |
Dclk3 |
doublecortin-like kinase 3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of DCLK3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:111,401,544...111,453,999
Ensembl chr 8:111,401,358...111,453,999
|
|
G |
Ddc |
dopa decarboxylase |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of DDC mRNA |
CTD |
PMID:31199487 |
|
NCBI chr14:86,378,685...86,469,189
Ensembl chr14:86,378,685...86,469,208
|
|
G |
Dhcr7 |
7-dehydrocholesterol reductase |
multiple interactions decreases expression |
EXP |
[diethyl phthalate co-treated with diisobutyl phthalate] results in decreased expression of DHCR7 mRNA diisobutyl phthalate results in decreased expression of DHCR7 mRNA |
CTD |
PMID:33983380 |
|
NCBI chr 1:199,015,081...199,031,055
Ensembl chr 1:199,015,081...199,031,055
|
|
G |
Dock3 |
dedicator of cyto-kinesis 3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of DOCK3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:107,552,462...107,903,527
Ensembl chr 8:107,552,463...107,903,514
|
|
G |
Dpf1 |
double PHD fingers 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of DPF1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:84,602,212...84,615,954
Ensembl chr 1:84,602,336...84,615,950
|
|
G |
Dync1i1 |
dynein cytoplasmic 1 intermediate chain 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of DYNC1I1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 4:33,852,597...34,166,159
Ensembl chr 4:33,852,927...34,166,149
|
|
G |
Ebp |
EBP, cholestenol delta-isomerase |
decreases expression |
EXP |
diisobutyl phthalate results in decreased expression of EBP mRNA |
CTD |
PMID:33983380 |
|
NCBI chr X:14,299,427...14,305,826
Ensembl chr X:14,299,448...14,305,826
|
|
G |
Ece2 |
endothelin-converting enzyme 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ECE2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr11:80,259,130...80,299,685
Ensembl chr11:80,263,162...80,278,428
|
|
G |
Edn1 |
endothelin 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of EDN1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Edn2 |
endothelin 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of EDN2 mRNA] |
CTD |
PMID:33316053 |
|
NCBI chr 5:133,751,316...133,756,814
Ensembl chr 5:133,751,217...133,756,814
|
|
G |
Elmod1 |
ELMO domain containing 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ELMOD1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:54,298,363...54,355,348
Ensembl chr 8:54,298,363...54,355,140
|
|
G |
Emx2 |
empty spiracles homeobox 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of EMX2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:258,626,584...258,633,594
Ensembl chr 1:258,626,584...258,633,594
|
|
G |
Epdr1 |
ependymin related 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of EPDR1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr17:45,333,677...45,358,597
Ensembl chr17:45,333,956...45,358,594
|
|
G |
Espn |
espin |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ESPN mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 5:162,626,560...162,660,439
Ensembl chr 5:162,626,560...162,660,256
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions increases activity |
ISO |
diisobutyl phthalate binds to and results in increased activity of ESR1 protein; diisobutyl phthalate inhibits the reaction [Estradiol results in increased activity of ESR1 protein]; Tamoxifen inhibits the reaction [diisobutyl phthalate binds to and results in increased activity of ESR1 protein] diisobutyl phthalate results in increased activity of ESR1 protein [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ESR1 mRNA |
CTD |
PMID:15840436 PMID:27633901 PMID:28013214 PMID:28571686 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions increases activity |
ISO |
diisobutyl phthalate binds to and results in increased activity of ESR2 protein; diisobutyl phthalate inhibits the reaction [Estradiol results in increased activity of ESR2 protein] diisobutyl phthalate results in increased activity of ESR2 protein |
CTD |
PMID:27633901 PMID:28571686 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Fabp5 |
fatty acid binding protein 5 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of FABP5 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 2:91,765,056...91,768,716
Ensembl chr 2:91,765,056...91,853,773
|
|
G |
Fam163a |
family with sequence similarity 163, member A |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of FAM163A mRNA |
CTD |
PMID:31199487 |
|
NCBI chr13:68,262,867...68,341,323
Ensembl chr13:68,262,872...68,341,049
|
|
G |
Fdps |
farnesyl diphosphate synthase |
decreases expression |
EXP |
diisobutyl phthalate results in decreased expression of FDPS mRNA |
CTD |
PMID:33983380 |
|
NCBI chr 2:174,497,402...174,507,031
Ensembl chr 2:174,486,665...174,507,776
|
|
G |
Fez1 |
fasciculation and elongation protein zeta 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of FEZ1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:36,544,462...36,589,684
Ensembl chr 8:36,544,535...36,589,683
|
|
G |
Fkbp1b |
FKBP prolyl isomerase 1B |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of FKBP1B mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 6:27,832,128...27,850,600
Ensembl chr 6:27,838,802...27,848,653
|
|
G |
Flg |
filaggrin |
multiple interactions |
ISO |
[FLG gene polymorphism affects the susceptibility to diisobutyl phthalate] which affects the abundance of mono-isobutyl phthalate |
CTD |
PMID:24380925 |
|
NCBI chr 2:178,888,688...178,912,731
|
|
G |
Fshb |
follicle stimulating hormone subunit beta |
multiple interactions |
ISO |
[Diethylhexyl Phthalate co-treated with diethyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate] results in decreased expression of FSHB protein |
CTD |
PMID:34597818 |
|
NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370
|
|
G |
Fshr |
follicle stimulating hormone receptor |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of FSHR mRNA |
CTD |
PMID:28013214 |
|
NCBI chr 6:5,198,825...5,406,785
Ensembl chr 6:5,198,825...5,406,785
|
|
G |
Fxyd7 |
FXYD domain-containing ion transport regulator 7 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of FXYD7 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:86,277,678...86,286,954
Ensembl chr 1:86,277,678...86,286,954
|
|
G |
Gfra3 |
GDNF family receptor alpha 3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of GFRA3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr18:26,297,828...26,326,105
Ensembl chr18:26,297,829...26,326,105
|
|
G |
Gfra4 |
GDNF family receptor alpha 4 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of GFRA4 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 3:118,254,937...118,262,252
Ensembl chr 3:118,255,402...118,258,329
|
|
G |
Ggta1 |
glycoprotein alpha-galactosyltransferase 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of GGTA1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 3:18,732,985...18,824,916
Ensembl chr 3:18,732,991...18,809,908
|
|
G |
Gng2 |
G protein subunit gamma 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of GNG2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr15:4,316,038...4,416,918
Ensembl chr15:4,316,059...4,417,183
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of GPX1 mRNA |
CTD |
PMID:28013214 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of GSR mRNA |
CTD |
PMID:28013214 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Gsta3 |
glutathione S-transferase alpha 3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of GSTA3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 9:23,658,574...23,684,240
Ensembl chr 9:23,658,574...23,684,240
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
decreases expression |
EXP |
diisobutyl phthalate results in decreased expression of HMGCR mRNA |
CTD |
PMID:28655647 PMID:33983380 |
|
NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
|
|
G |
Hmgcs1 |
3-hydroxy-3-methylglutaryl-CoA synthase 1 |
decreases expression |
EXP |
diisobutyl phthalate results in decreased expression of HMGCS1 mRNA |
CTD |
PMID:28655647 PMID:33983380 |
|
NCBI chr 2:51,649,368...51,667,100
Ensembl chr 2:51,649,497...51,667,100
|
|
G |
Hoxb8 |
homeo box B8 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of HOXB8 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr10:81,248,313...81,251,261
Ensembl chr10:81,248,887...81,250,638
|
|
G |
Hoxd3 |
homeo box D3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of HOXD3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 3:59,638,708...59,650,282
Ensembl chr 3:59,638,708...59,650,282
|
|
G |
Hsd17b3 |
hydroxysteroid (17-beta) dehydrogenase 3 |
increases expression |
EXP |
diisobutyl phthalate results in increased expression of HSD17B3 mRNA |
CTD |
PMID:28655647 |
|
NCBI chr17:1,027,229...1,058,554
Ensembl chr17:1,027,229...1,058,554
|
|
G |
Hsd3b1 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 |
multiple interactions |
ISO EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of HSD3B1 mRNA [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of HSD3B1 mRNA |
CTD |
PMID:28013214 PMID:35762964 |
|
NCBI chr 2:186,169,864...186,175,984
Ensembl chr 2:186,169,863...186,175,999
|
|
G |
Hsd3b3 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 3 |
multiple interactions decreases expression |
EXP |
[diethyl phthalate co-treated with diisobutyl phthalate] results in decreased expression of HSD3B3 mRNA diisobutyl phthalate results in decreased expression of HSD3B3 mRNA |
CTD |
PMID:33983380 |
|
NCBI chr 2:186,138,044...186,144,024
Ensembl chr 2:186,138,044...186,144,033
|
|
G |
Hspa12a |
heat shock protein family A (Hsp70) member 12A |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of HSPA12A mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:257,935,642...258,096,602
Ensembl chr 1:257,935,644...258,096,846
|
|
G |
Ido2 |
indoleamine 2,3-dioxygenase 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of IDO2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr16:67,459,158...67,498,052
Ensembl chr16:67,459,190...67,496,324
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of IL6 mRNA] |
CTD |
PMID:33316053 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Inha |
inhibin subunit alpha |
decreases expression |
EXP |
diisobutyl phthalate results in decreased expression of INHA mRNA |
CTD |
PMID:33983380 |
|
NCBI chr 9:76,994,465...76,997,366
Ensembl chr 9:76,993,589...76,997,248
|
|
G |
Insig1 |
insulin induced gene 1 |
decreases expression |
EXP |
diisobutyl phthalate results in decreased expression of INSIG1 mRNA |
CTD |
PMID:33983380 |
|
NCBI chr 4:7,315,494...7,323,972
Ensembl chr 4:7,315,495...7,323,952
|
|
G |
Insl3 |
insulin-like 3 |
decreases expression multiple interactions |
EXP |
diisobutyl phthalate results in decreased expression of INSL3 mRNA [diethyl phthalate co-treated with diisobutyl phthalate] results in decreased expression of INSL3 mRNA |
CTD |
PMID:22112501 PMID:33983380 |
|
NCBI chr16:18,398,682...18,400,566
Ensembl chr16:18,384,829...18,400,560
|
|
G |
Kif5c |
kinesin family member 5C |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of KIF5C mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 3:34,032,082...34,185,597
Ensembl chr 3:34,032,105...34,182,413
|
|
G |
L1cam |
L1 cell adhesion molecule |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of L1CAM mRNA |
CTD |
PMID:31199487 |
|
NCBI chr X:151,597,270...151,623,776
Ensembl chr X:151,597,277...151,623,857
|
|
G |
Lcn2 |
lipocalin 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of LCN2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 3:15,680,688...15,684,033
Ensembl chr 3:15,680,687...15,684,095
|
|
G |
Ldlr |
low density lipoprotein receptor |
decreases expression |
EXP |
diisobutyl phthalate results in decreased expression of LDLR mRNA |
CTD |
PMID:33983380 |
|
NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580
|
|
G |
Lhcgr |
luteinizing hormone/choriogonadotropin receptor |
multiple interactions |
EXP |
[diethyl phthalate co-treated with diisobutyl phthalate] results in decreased expression of LHCGR mRNA |
CTD |
PMID:33983380 |
|
NCBI chr 6:5,661,871...5,728,109
Ensembl chr 6:5,661,871...5,724,521
|
|
G |
Lonrf2 |
LON peptidase N-terminal domain and ring finger 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of LONRF2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 9:41,033,125...41,070,551
Ensembl chr 9:41,034,628...41,070,649
|
|
G |
Lpl |
lipoprotein lipase |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of LPL mRNA |
CTD |
PMID:30768133 |
|
NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249
|
|
G |
Lrrc4b |
leucine rich repeat containing 4B |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of LRRC4B mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:94,922,034...94,956,309
Ensembl chr 1:94,935,603...94,956,263
|
|
G |
Lynx1 |
Ly6/neurotoxin 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of LYNX1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 7:106,632,800...106,638,003
Ensembl chr 7:106,632,797...106,638,023
|
|
G |
Map6 |
microtubule-associated protein 6 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of MAP6 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:153,568,019...153,634,415
Ensembl chr 1:153,568,368...153,634,414
|
|
G |
Mapt |
microtubule-associated protein tau |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of MAPT mRNA |
CTD |
PMID:31199487 |
|
NCBI chr10:89,138,644...89,236,137
Ensembl chr10:89,138,627...89,236,129
|
|
G |
Mir141 |
microRNA 141 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of MIR141 |
CTD |
PMID:31199487 |
|
NCBI chr 4:157,523,239...157,523,332
Ensembl chr 4:157,523,239...157,523,332
|
|
G |
Mir184 |
microRNA 184 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of MIR184; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of MIR184 mRNA |
CTD |
PMID:31199487 PMID:35762964 |
|
NCBI chr 8:90,343,134...90,343,210
Ensembl chr 8:90,343,134...90,343,210
|
|
G |
Mllt11 |
MLLT11, transcription factor 7 cofactor |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of MLLT11 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 2:182,795,790...182,804,960
Ensembl chr 2:182,795,790...182,797,199
|
|
G |
Mmp14 |
matrix metallopeptidase 14 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] promotes the reaction [CGA protein results in increased expression of MMP14 mRNA] |
CTD |
PMID:33316053 |
|
NCBI chr15:27,887,795...27,897,020
Ensembl chr15:27,887,727...27,899,864
|
|
G |
Mmp16 |
matrix metallopeptidase 16 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] promotes the reaction [CGA protein results in increased expression of MMP16 mRNA] |
CTD |
PMID:33316053 |
|
NCBI chr 5:31,312,280...31,556,276
Ensembl chr 5:31,312,280...31,548,388
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of MMP9 mRNA] |
CTD |
PMID:33316053 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mvd |
mevalonate diphosphate decarboxylase |
decreases expression |
EXP |
diisobutyl phthalate results in decreased expression of MVD mRNA |
CTD |
PMID:33983380 |
|
NCBI chr19:50,496,366...50,506,389
Ensembl chr19:50,496,367...50,507,971
|
|
G |
Ncs1 |
neuronal calcium sensor 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of NCS1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 3:14,523,220...14,568,829
Ensembl chr 3:14,523,220...14,568,829
|
|
G |
Ndrg4 |
NDRG family member 4 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of NDRG4 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr19:9,351,408...9,387,398
Ensembl chr19:9,351,404...9,386,914
|
|
G |
Nefh |
neurofilament heavy chain |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of NEFH mRNA |
CTD |
PMID:31199487 |
|
NCBI chr14:79,830,362...79,840,347
Ensembl chr14:79,830,362...79,840,351
|
|
G |
Nefl |
neurofilament light chain |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of NEFL mRNA |
CTD |
PMID:31199487 |
|
NCBI chr15:42,301,920...42,305,793
Ensembl chr15:42,301,916...42,305,793
|
|
G |
Nell1 |
neural EGFL like 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of NELL1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:99,709,305...100,573,872
Ensembl chr 1:99,709,793...100,573,860
|
|
G |
Ngfr |
nerve growth factor receptor |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of NGFR mRNA |
CTD |
PMID:31199487 |
|
NCBI chr10:80,515,287...80,533,518
Ensembl chr10:80,515,299...80,533,518
|
|
G |
Nr0b1 |
nuclear receptor subfamily 0, group B, member 1 |
decreases expression |
EXP |
diisobutyl phthalate results in decreased expression of NR0B1 mRNA |
CTD |
PMID:33983380 |
|
NCBI chr X:50,756,886...50,761,014
Ensembl chr X:50,756,886...50,761,011
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
increases activity |
ISO |
diisobutyl phthalate results in increased activity of NR1I2 protein alternative form |
CTD |
PMID:21227907 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
multiple interactions increases activity affects binding |
ISO |
[diisobutyl phthalate co-treated with Androstanols] results in increased activity of NR1I3 protein alternative form diisobutyl phthalate results in increased activity of NR1I3 protein alternative form diisobutyl phthalate binds to NR1I3 protein |
CTD |
PMID:21227907 PMID:25938866 |
|
NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906
|
|
G |
Nrxn2 |
neurexin 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of NRXN2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:203,726,420...203,842,301
Ensembl chr 1:203,735,753...203,842,297
|
|
G |
Nsdhl |
NAD(P) dependent steroid dehydrogenase-like |
decreases expression |
EXP |
diisobutyl phthalate results in decreased expression of NSDHL mRNA |
CTD |
PMID:33983380 |
|
NCBI chr X:150,775,034...150,807,161
Ensembl chr X:150,775,080...150,807,142
|
|
G |
Nsg1 |
neuronal vesicle trafficking associated 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of NSG1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr14:72,648,771...72,670,521
Ensembl chr14:72,648,741...72,670,514
|
|
G |
Nsg2 |
neuronal vesicle trafficking associated 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of NSG2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr10:15,601,594...15,661,441
Ensembl chr10:15,601,596...15,661,441
|
|
G |
Olfm1 |
olfactomedin 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of OLFM1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 3:11,520,522...11,558,240
Ensembl chr 3:11,520,729...11,558,239
|
|
G |
Pcp4 |
Purkinje cell protein 4 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PCP4 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr11:35,759,711...35,861,725
Ensembl chr11:35,800,713...35,861,725
|
|
G |
Pgr |
progesterone receptor |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of PGR mRNA] |
CTD |
PMID:33316053 |
|
NCBI chr 8:6,073,216...6,131,552
Ensembl chr 8:6,072,673...6,131,344
|
|
G |
Plat |
plasminogen activator, tissue type |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of PLAT mRNA] |
CTD |
PMID:33316053 |
|
NCBI chr16:69,240,582...69,265,177
Ensembl chr16:69,240,585...69,268,223
|
|
G |
Plppr3 |
phospholipid phosphatase related 3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PLPPR3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 7:9,831,162...9,842,434
Ensembl chr 7:9,831,162...9,845,296
|
|
G |
Pls1 |
plastin 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PLS1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:96,316,703...96,426,592
Ensembl chr 8:96,317,849...96,385,195
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PPARA mRNA |
CTD |
PMID:28013214 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions increases expression increases activity |
ISO |
diisobutyl phthalate binds to and results in increased activity of PPARG protein diisobutyl phthalate results in increased expression of PPARG protein diisobutyl phthalate results in increased activity of PPARG protein |
CTD |
PMID:24155963 PMID:26172262 PMID:27633901 PMID:29061543 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppp2r2b |
protein phosphatase 2, regulatory subunit B, beta |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PPP2R2B mRNA |
CTD |
PMID:31199487 |
|
NCBI chr18:34,653,716...35,080,889
Ensembl chr18:34,653,721...35,081,025
|
|
G |
Prima1 |
proline rich membrane anchor 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PRIMA1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 6:122,338,365...122,390,955
Ensembl chr 6:122,338,370...122,389,921
|
|
G |
Prph |
peripherin |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PRPH mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 7:130,218,149...130,222,136
Ensembl chr 7:130,218,357...130,222,136
|
|
G |
Ptges |
prostaglandin E synthase |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PTGES mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 3:14,177,892...14,189,236
|
|
G |
Ptgr1 |
prostaglandin reductase 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PTGR1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 5:73,784,000...73,802,624
Ensembl chr 5:73,784,009...73,802,666
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of PTGS2 mRNA] |
CTD |
PMID:33316053 |
|
NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Ptprn |
protein tyrosine phosphatase, receptor type, N |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PTPRN mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 9:76,741,010...76,756,704
Ensembl chr 9:76,741,016...76,756,190
|
|
G |
Qsox1 |
quiescin sulfhydryl oxidase 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of QSOX1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr13:67,949,780...67,987,434
Ensembl chr13:67,949,780...67,987,459
|
|
G |
Rab3b |
RAB3B, member RAS oncogene family |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of RAB3B mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 5:123,629,562...123,697,410
Ensembl chr 5:123,644,423...123,697,401
|
|
G |
Rab6b |
RAB6B, member RAS oncogene family |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of RAB6B mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:103,695,328...103,764,023
Ensembl chr 8:103,695,631...103,805,732
|
|
G |
Rassf4 |
Ras association domain family member 4 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of RASSF4 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 4:149,897,525...149,932,658
Ensembl chr 4:149,897,543...149,932,411
|
|
G |
Resp18 |
regulated endocrine-specific protein 18 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of RESP18 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 9:76,765,179...76,771,824
Ensembl chr 9:76,764,590...76,778,722
|
|
G |
Rnf183 |
ring finger protein 183 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of RNF183 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 5:75,877,111...75,886,253
Ensembl chr 5:75,876,003...75,886,191
|
|
G |
Rtn1 |
reticulon 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of RTN1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 6:90,763,212...90,983,436
Ensembl chr 6:90,763,216...90,983,436
|
|
G |
Rtn4r |
reticulon 4 receptor |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of RTN4R mRNA |
CTD |
PMID:31199487 |
|
NCBI chr11:82,844,585...82,869,012
Ensembl chr11:82,844,309...82,869,466
|
|
G |
Rxrg |
retinoid X receptor gamma |
decreases expression |
EXP |
diisobutyl phthalate results in decreased expression of RXRG mRNA |
CTD |
PMID:22112501 |
|
NCBI chr13:79,743,430...79,785,173
Ensembl chr13:79,743,563...79,785,167
|
|
G |
Scarb1 |
scavenger receptor class B, member 1 |
decreases expression multiple interactions |
EXP |
diisobutyl phthalate results in decreased expression of SCARB1 mRNA [diethyl phthalate co-treated with diisobutyl phthalate] results in decreased expression of SCARB1 mRNA |
CTD |
PMID:22112501 PMID:28655647 PMID:33983380 |
|
NCBI chr12:31,296,143...31,362,649
Ensembl chr12:31,296,156...31,362,647
|
|
G |
Scg3 |
secretogranin III |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SCG3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:76,399,777...76,442,015
Ensembl chr 8:76,399,777...76,442,015
|
|
G |
Scn3b |
sodium voltage-gated channel beta subunit 3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SCN3B mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:40,630,372...40,652,869
Ensembl chr 8:40,630,455...40,652,868
|
|
G |
Scrn1 |
secernin 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SCRN1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 4:83,632,125...83,694,225
Ensembl chr 4:83,632,131...83,693,852
|
|
G |
Serpinb2 |
serpin family B member 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of SERPINB2 mRNA] |
CTD |
PMID:33316053 |
|
NCBI chr13:23,537,312...23,551,823
Ensembl chr13:23,541,400...23,550,408
|
|
G |
Serpine1 |
serpin family E member 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of SERPINE1 mRNA] |
CTD |
PMID:33316053 |
|
NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657
|
|
G |
Sh3gl3 |
SH3 domain containing GRB2 like 3, endophilin A3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SH3GL3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:136,124,502...136,255,669
Ensembl chr 1:136,124,499...136,255,584
|
|
G |
Sh3tc2 |
SH3 domain and tetratricopeptide repeats 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SH3TC2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr18:55,416,383...55,477,419
Ensembl chr18:55,416,413...55,483,083
|
|
G |
Shc2 |
SHC adaptor protein 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SHC2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 7:10,066,705...10,088,926
Ensembl chr 7:10,066,705...10,088,926
|
|
G |
Slc13a2 |
solute carrier family 13 member 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SLC13A2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr10:63,291,813...63,319,127
Ensembl chr10:63,291,815...63,319,127
|
|
G |
Slc29a4 |
solute carrier family 29 member 4 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SLC29A4 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr12:11,853,540...11,884,660
Ensembl chr12:11,853,540...11,874,834
|
|
G |
Slc5a7 |
solute carrier family 5 member 7 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SLC5A7 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 9:7,595,440...7,626,258
Ensembl chr 9:7,595,444...7,626,258
|
|
G |
Slco2a1 |
solute carrier organic anion transporter family, member 2a1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] promotes the reaction [CGA protein results in increased expression of SLCO2A1 mRNA] |
CTD |
PMID:33316053 |
|
NCBI chr 8:103,588,916...103,672,546
Ensembl chr 8:103,588,916...103,672,546
|
|
G |
Smim24 |
small integral membrane protein 24 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SMIM24 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 7:8,310,530...8,316,686
|
|
G |
Snhg11 |
small nucleolar RNA host gene 11 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SNHG11 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 3:147,031,411...147,037,809
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SOD1 mRNA |
CTD |
PMID:28013214 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Sox9 |
SRY-box transcription factor 9 |
increases expression |
EXP |
diisobutyl phthalate results in increased expression of SOX9 mRNA |
CTD |
PMID:22112501 |
|
NCBI chr10:97,806,485...97,811,994
Ensembl chr10:97,806,485...97,811,994
|
|
G |
Star |
steroidogenic acute regulatory protein |
decreases expression multiple interactions |
EXP ISO |
diisobutyl phthalate results in decreased expression of STAR mRNA; diisobutyl phthalate results in decreased expression of STAR protein [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of STAR mRNA; [diethyl phthalate co-treated with diisobutyl phthalate] results in decreased expression of STAR mRNA [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of STAR mRNA; [Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diethyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in decreased expression of STAR mRNA; [Diethylhexyl Phthalate co-treated with diethyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate] results in decreased expression of STAR mRNA |
CTD |
PMID:16458459 PMID:21633115 PMID:22112501 PMID:28013214 PMID:28655647 PMID:30802670 PMID:33983380 PMID:34597818 PMID:35762964 More...
|
|
NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672
|
|
G |
Stk32c |
serine/threonine kinase 32C |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of STK32C mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:193,900,718...193,981,723
Ensembl chr 1:193,900,718...193,981,723
|
|
G |
Stmn4 |
stathmin 4 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of STMN4 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr15:40,541,305...40,559,253
Ensembl chr15:40,541,357...40,559,253
|
|
G |
Syt11 |
synaptotagmin 11 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SYT11 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 2:174,206,032...174,232,540
Ensembl chr 2:174,206,191...174,231,964
|
|
G |
Syt5 |
synaptotagmin 5 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SYT5 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:69,277,351...69,285,071
Ensembl chr 1:69,277,351...69,285,067
|
|
G |
Tbx2 |
T-box transcription factor 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TBX2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr10:70,679,670...70,688,868
Ensembl chr10:70,679,518...70,688,529
|
|
G |
Tcf23 |
transcription factor 23 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TCF23 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 6:25,397,889...25,406,639
Ensembl chr 6:25,397,937...25,405,880
|
|
G |
Tcte1 |
t-complex-associated testis expressed 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TCTE1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 9:15,463,573...15,482,258
Ensembl chr 9:15,463,739...15,472,954
|
|
G |
Thrb |
thyroid hormone receptor beta |
multiple interactions |
ISO |
diisobutyl phthalate binds to and results in decreased activity of THRB protein |
CTD |
PMID:27633901 |
|
NCBI chr15:7,685,180...8,031,920
Ensembl chr15:7,685,180...7,882,916
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of TIMP1 mRNA] |
CTD |
PMID:33316053 |
|
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
|
|
G |
Tm7sf2 |
transmembrane 7 superfamily member 2 |
decreases expression |
EXP |
diisobutyl phthalate results in decreased expression of TM7SF2 mRNA |
CTD |
PMID:33983380 |
|
NCBI chr 1:203,355,930...203,360,287
Ensembl chr 1:203,355,931...203,360,270
|
|
G |
Tmeff2 |
transmembrane protein with EGF-like and two follistatin-like domains 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TMEFF2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 9:50,445,550...50,733,482
Ensembl chr 9:50,436,079...50,733,475
|
|
G |
Tmem130 |
transmembrane protein 130 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TMEM130 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr12:9,837,055...9,862,843
Ensembl chr12:9,837,055...9,862,840
|
|
G |
Tmem35a |
transmembrane protein 35A |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TMEM35A mRNA |
CTD |
PMID:31199487 |
|
NCBI chr X:97,503,350...97,514,198
Ensembl chr X:97,503,350...97,514,197
|
|
G |
Tmem63c |
transmembrane protein 63c |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TMEM63C mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 6:106,667,389...106,738,778
Ensembl chr 6:106,672,934...106,736,990
|
|
G |
Trpc6 |
transient receptor potential cation channel, subfamily C, member 6 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TRPC6 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:5,759,387...5,864,000
Ensembl chr 8:5,758,935...5,828,092
|
|
G |
Ttyh1 |
tweety family member 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TTYH1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:70,053,312...70,071,872
Ensembl chr 1:70,053,324...70,071,845
|
|
G |
Tubb2b |
tubulin, beta 2B class IIb |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TUBB2B mRNA |
CTD |
PMID:31199487 |
|
NCBI chr17:30,747,734...30,750,781
Ensembl chr17:30,747,734...30,750,638
|
|
G |
Tubb3 |
tubulin, beta 3 class III |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TUBB3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr19:51,457,187...51,466,243
Ensembl chr19:51,457,184...51,466,243
|
|
G |
Tubb4a |
tubulin, beta 4A class IVa |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TUBB4A mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 9:1,917,841...1,925,286
Ensembl chr 9:1,917,845...1,925,291
|
|
G |
Ubash3b |
ubiquitin associated and SH3 domain containing, B |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of UBASH3B mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:41,385,419...41,532,248
Ensembl chr 8:41,388,341...41,532,201
|
|
G |
Ubxn11 |
UBX domain protein 11 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of UBXN11 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 5:146,329,666...146,353,529
Ensembl chr 5:146,329,842...146,353,526
|
|
G |
Wnt4 |
Wnt family member 4 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of WNT4 mRNA] |
CTD |
PMID:33316053 |
|
NCBI chr 5:149,513,573...149,535,415
Ensembl chr 5:149,514,018...149,532,859
|
|
G |
Wnt6 |
Wnt family member 6 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of WNT6 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 9:76,329,882...76,343,523
Ensembl chr 9:76,329,882...76,343,523
|
|
G |
Wnt9b |
Wnt family member 9B |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of WNT9B mRNA |
CTD |
PMID:31199487 |
|
NCBI chr10:88,635,330...88,657,035
Ensembl chr10:88,635,331...88,657,035
|
|
G |
Wt1 |
WT1 transcription factor |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of WT1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 3:91,566,540...91,613,653
Ensembl chr 3:91,567,001...91,613,643
|
|
G |
Zcchc12 |
zinc finger CCHC-type containing 12 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ZCCHC12 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr X:115,433,444...115,436,691
Ensembl chr X:115,433,259...115,436,692
|
|
G |
Zfat |
zinc finger and AT hook domain containing |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of ZFAT mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 7:99,886,954...100,054,288
Ensembl chr 7:99,886,954...100,054,274
|
|
G |
Zp2 |
zona pellucida glycoprotein 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ZP2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:174,513,507...174,525,288
Ensembl chr 1:174,513,511...174,525,288
|
|
|
G |
Atg13 |
autophagy related 13 |
multiple interactions |
ISO |
ATG13 protein inhibits the reaction [Nitrogen deficiency results in decreased expression of ULK1 protein]; ATG13 protein promotes the reaction [bafilomycin A inhibits the reaction [Nitrogen deficiency results in decreased expression of ULK1 protein]]; Nitrogen deficiency inhibits the reaction [ATG13 protein results in increased expression of ULK1 protein]; Nitrogen deficiency promotes the reaction [ATG13 protein results in decreased expression of SQSTM1 protein] |
CTD |
PMID:27629431 |
|
NCBI chr 3:77,647,069...77,681,028
Ensembl chr 3:77,645,790...77,681,043
|
|
G |
Atg4b |
autophagy related 4B, cysteine peptidase |
decreases expression |
ISO |
Nitrogen deficiency results in decreased expression of ATG4B protein |
CTD |
PMID:27629431 |
|
NCBI chr 9:94,282,417...94,314,109
Ensembl chr 9:94,282,509...94,314,103
|
|
G |
Atg7 |
autophagy related 7 |
multiple interactions |
ISO |
ATG7 protein inhibits the reaction [Nitrogen deficiency results in decreased expression of ULK1 protein]; ATG7 protein promotes the reaction [bafilomycin A inhibits the reaction [Nitrogen deficiency results in decreased expression of ULK1 protein]] |
CTD |
PMID:27629431 |
|
NCBI chr 4:147,718,663...147,925,656
Ensembl chr 4:147,718,752...147,925,593
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
[Silver Compounds binds to [Nitrogen binds to titanium dioxide]] which results in increased secretion of CCL2 protein |
CTD |
PMID:30711708 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
multiple interactions |
ISO |
[Silver Compounds binds to [Nitrogen binds to titanium dioxide]] which results in increased secretion of CCL5 protein |
CTD |
PMID:30711708 |
|
NCBI chr10:68,322,826...68,327,365
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
multiple interactions |
ISO |
[Nanotubes, Carbon co-treated with Nitrogen] results in increased expression of CDK4 protein |
CTD |
PMID:25797581 |
|
NCBI chr 7:62,885,647...62,889,562
Ensembl chr 7:62,883,105...62,942,403
|
|
G |
Csf2 |
colony stimulating factor 2 |
multiple interactions |
ISO |
[Silver Compounds binds to [Nitrogen binds to titanium dioxide]] which results in increased secretion of CSF2 protein |
CTD |
PMID:30711708 |
|
NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199
|
|
G |
Csf3 |
colony stimulating factor 3 |
multiple interactions |
ISO |
[Silver Compounds binds to [Nitrogen binds to titanium dioxide]] which results in increased secretion of CSF3 protein |
CTD |
PMID:30711708 |
|
NCBI chr10:83,660,787...83,664,569
Ensembl chr10:83,661,207...83,663,603
|
|
G |
Cxcl1 |
C-X-C motif chemokine ligand 1 |
multiple interactions |
ISO |
[Silver Compounds binds to [Nitrogen binds to titanium dioxide]] which results in increased secretion of CXCL1 protein |
CTD |
PMID:30711708 |
|
NCBI chr14:17,193,364...17,195,143
Ensembl chr14:17,193,365...17,195,215
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
multiple interactions |
ISO |
[Silver Compounds binds to [Nitrogen binds to titanium dioxide]] which results in increased secretion of CXCL1 protein |
CTD |
PMID:30711708 |
|
NCBI chr14:17,270,146...17,289,458
Ensembl chr14:17,270,146...17,289,511
|
|
G |
Grk1 |
G protein-coupled receptor kinase 1 |
multiple interactions |
ISO |
[Nitrogen co-treated with Iodoacetic Acid] results in increased expression of GRK1 mRNA; Octreotide affects the reaction [SSTR1 protein affects the reaction [[Nitrogen co-treated with Iodoacetic Acid] results in increased expression of GRK1 mRNA]]; Octreotide inhibits the reaction [[Nitrogen co-treated with Iodoacetic Acid] results in increased expression of GRK1 mRNA]; SSTR1 protein affects the reaction [[Nitrogen co-treated with Iodoacetic Acid] results in increased expression of GRK1 mRNA] |
CTD |
PMID:18624922 |
|
NCBI chr16:76,122,501...76,135,792
Ensembl chr16:76,123,842...76,135,792
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
[Silver Compounds binds to [Nitrogen binds to titanium dioxide]] which results in increased secretion of IL6 protein |
CTD |
PMID:30711708 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
[Silver Compounds binds to [Nitrogen binds to titanium dioxide]] which results in increased phosphorylation of MAPK1 protein |
CTD |
PMID:30711708 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
[Silver Compounds binds to [Nitrogen binds to titanium dioxide]] which results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:30711708 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mif |
macrophage migration inhibitory factor |
multiple interactions |
ISO |
[Silver Compounds binds to [Nitrogen binds to titanium dioxide]] which results in increased secretion of MIF protein |
CTD |
PMID:30711708 |
|
NCBI chr20:12,790,919...12,791,784
Ensembl chr20:12,790,902...12,799,504
|
|
G |
Rgs1 |
regulator of G-protein signaling 1 |
multiple interactions |
ISO |
[Nitrogen co-treated with Iodoacetic Acid] results in increased expression of RGS1 mRNA; Octreotide inhibits the reaction [[Nitrogen co-treated with Iodoacetic Acid] results in increased expression of RGS1 mRNA]; SSTR1 protein affects the reaction [[Nitrogen co-treated with Iodoacetic Acid] results in increased expression of RGS1 mRNA] |
CTD |
PMID:18624922 |
|
NCBI chr13:56,018,529...56,022,939
Ensembl chr13:56,018,554...56,022,984
|
|
G |
Serpine1 |
serpin family E member 1 |
multiple interactions |
ISO |
[Silver Compounds binds to [Nitrogen binds to titanium dioxide]] which results in increased secretion of SERPINE1 protein |
CTD |
PMID:30711708 |
|
NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657
|
|
G |
Sqstm1 |
sequestosome 1 |
multiple interactions decreases expression |
ISO |
bafilomycin A inhibits the reaction [Nitrogen deficiency results in decreased expression of SQSTM1 protein]; Nitrogen deficiency promotes the reaction [ATG13 protein results in decreased expression of SQSTM1 protein] |
CTD |
PMID:27629431 |
|
NCBI chr10:34,525,517...34,536,685
Ensembl chr10:34,525,519...34,536,673
|
|
G |
Sstr1 |
somatostatin receptor 1 |
multiple interactions |
ISO |
Octreotide affects the reaction [SSTR1 protein affects the reaction [[Nitrogen co-treated with Iodoacetic Acid] results in increased expression of GRK1 mRNA]]; SSTR1 protein affects the reaction [[Nitrogen co-treated with Iodoacetic Acid] results in increased expression of GRK1 mRNA]; SSTR1 protein affects the reaction [[Nitrogen co-treated with Iodoacetic Acid] results in increased expression of RGS1 mRNA] |
CTD |
PMID:18624922 |
|
NCBI chr 6:75,832,292...75,836,806
Ensembl chr 6:75,832,530...75,836,802
|
|
G |
Txnrd1 |
thioredoxin reductase 1 |
multiple interactions |
EXP |
Nitrogen inhibits the reaction [myricetin results in decreased activity of TXNRD1 protein modified form]; Nitrogen inhibits the reaction [Quercetin results in decreased activity of TXNRD1 protein modified form] |
CTD |
PMID:16618767 |
|
NCBI chr 7:20,830,042...20,914,990
Ensembl chr 7:20,830,045...20,907,863
|
|
G |
Ulk1 |
unc-51 like autophagy activating kinase 1 |
multiple interactions increases expression |
ISO |
Antimycin A inhibits the reaction [Nitrogen deficiency results in decreased expression of ULK1 protein]; ATG13 protein inhibits the reaction [Nitrogen deficiency results in decreased expression of ULK1 protein]; ATG13 protein promotes the reaction [bafilomycin A inhibits the reaction [Nitrogen deficiency results in decreased expression of ULK1 protein]]; ATG7 protein inhibits the reaction [Nitrogen deficiency results in decreased expression of ULK1 protein]; ATG7 protein promotes the reaction [bafilomycin A inhibits the reaction [Nitrogen deficiency results in decreased expression of ULK1 protein]]; bafilomycin A inhibits the reaction [Nitrogen deficiency results in decreased expression of ULK1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Nitrogen deficiency results in decreased expression of ULK1 protein]; Nitrogen deficiency inhibits the reaction [Antimycin A results in increased expression of ULK1 protein]; Nitrogen deficiency inhibits the reaction [ATG13 protein results in increased expression of ULK1 protein]; Nitrogen deficiency results in decreased expression of and results in decreased phosphorylation of and results in increased cleavage of and affects the localization of ULK1 protein Nitrogen deficiency results in increased expression of ULK1 mRNA |
CTD |
PMID:27629431 |
|
NCBI chr12:45,851,710...45,877,966
Ensembl chr12:45,851,710...45,877,966
|
|
|
G |
Cntf |
ciliary neurotrophic factor |
multiple interactions decreases activity |
ISO |
Nitrous Oxide inhibits the reaction [CNTF protein results in increased phosphorylation of and results in increased activity of STAT1 protein]; Nitrous Oxide inhibits the reaction [CNTF protein results in increased phosphorylation of and results in increased activity of STAT3 protein] Nitrous Oxide inhibits the reaction [CNTF protein results in increased activity of STAT3 protein] Nitrous Oxide results in decreased activity of CNTF protein |
CTD |
PMID:15748169 |
|
NCBI chr 1:209,887,854...209,889,877
Ensembl chr 1:209,887,854...209,889,877
|
|
G |
Gabra4 |
gamma-aminobutyric acid type A receptor subunit alpha 4 |
multiple interactions |
ISO |
[Isoflurane co-treated with Nitrous Oxide] affects the expression of GABRA4 mRNA |
CTD |
PMID:16733821 |
|
NCBI chr14:36,590,782...36,667,724
Ensembl chr14:36,590,782...36,665,844
|
|
G |
Grin2a |
glutamate ionotropic receptor NMDA type subunit 2A |
multiple interactions |
ISO |
GRIN2A protein affects the susceptibility to [Nitrous Oxide co-treated with sevoflurane] |
CTD |
PMID:15731593 |
|
NCBI chr10:5,630,684...6,043,341
Ensembl chr10:5,631,369...6,044,637
|
|
G |
Mtr |
5-methyltetrahydrofolate-homocysteine methyltransferase |
decreases activity |
ISO |
Nitrous Oxide results in decreased activity of MTR protein |
CTD |
PMID:18472229 |
|
NCBI chr17:58,219,998...58,308,560
Ensembl chr17:58,220,071...58,304,822
|
|
G |
Pla2g7 |
phospholipase A2 group VII |
affects expression |
ISO |
Nitrous Oxide affects the expression of PLA2G7 |
CTD |
PMID:21356620 |
|
NCBI chr 9:17,362,214...17,404,476
Ensembl chr 9:17,362,225...17,404,476
|
|
G |
Pomc |
proopiomelanocortin |
increases secretion |
EXP |
Nitrous Oxide results in increased secretion of POMC protein |
CTD |
PMID:2846107 |
|
NCBI chr 6:26,939,844...26,945,666
Ensembl chr 6:26,939,837...26,945,664
|
|
G |
Stat1 |
signal transducer and activator of transcription 1 |
multiple interactions |
ISO |
Nitrous Oxide inhibits the reaction [CNTF protein results in increased phosphorylation of and results in increased activity of STAT1 protein] |
CTD |
PMID:15748169 |
|
NCBI chr 9:49,419,561...49,459,969
Ensembl chr 9:49,419,340...49,588,540
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions |
ISO |
Nitrous Oxide inhibits the reaction [CNTF protein results in increased activity of STAT3 protein] Nitrous Oxide inhibits the reaction [CNTF protein results in increased phosphorylation of and results in increased activity of STAT3 protein] |
CTD |
PMID:15748169 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
increases expression |
ISO |
fenpyroximate results in increased expression of ABCA1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Ache |
acetylcholinesterase |
decreases activity |
EXP |
fenpyroximate results in decreased activity of ACHE protein |
CTD |
PMID:35580743 |
|
NCBI chr12:19,407,359...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Akr1b1 |
aldo-keto reductase family 1 member B1 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of AKR1B1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 4:62,932,033...62,946,126
Ensembl chr 4:62,932,031...62,946,157
|
|
G |
Akr7a2 |
aldo-keto reductase family 7, member A2 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of AKR7A2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 5:151,552,375...151,560,914
Ensembl chr 5:151,552,343...151,560,909
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of AKT1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Aldh9a1 |
aldehyde dehydrogenase 9 family, member A1 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of ALDH9A1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr13:79,505,738...79,522,539
Ensembl chr13:79,505,695...79,540,568
|
|
G |
Amer1 |
APC membrane recruitment protein 1 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of AMER1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr X:60,300,595...60,316,480
Ensembl chr X:60,295,751...60,316,440
|
|
G |
Ano10 |
anoctamin 10 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of ANO10 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 8:121,841,664...121,960,739
Ensembl chr 8:121,841,665...121,962,670
|
|
G |
Ap3m1 |
adaptor related protein complex 3 subunit mu 1 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of AP3M1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr15:3,246,616...3,264,846
Ensembl chr15:3,246,926...3,264,844
|
|
G |
Apex1 |
apurinic/apyrimidinic endodeoxyribonuclease 1 |
increases expression |
ISO |
fenpyroximate results in increased expression of APEX1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr15:24,144,595...24,146,785
Ensembl chr15:24,144,362...24,146,785
|
|
G |
Arg1 |
arginase 1 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of ARG1 mRNA |
CTD |
PMID:32194361 |
|
NCBI chr 1:20,475,878...20,488,422
Ensembl chr 1:20,475,968...20,488,422
|
|
G |
Arhgap9 |
Rho GTPase activating protein 9 |
increases expression |
ISO |
fenpyroximate results in increased expression of ARHGAP9 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 7:63,148,573...63,157,025
Ensembl chr 7:63,148,900...63,157,524
|
|
G |
Arrdc4 |
arrestin domain containing 4 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of ARRDC4 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:122,369,355...122,383,351
Ensembl chr 1:122,369,360...122,383,290
|
|
G |
Asns |
asparagine synthetase (glutamine-hydrolyzing) |
increases expression |
ISO |
fenpyroximate results in increased expression of ASNS mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 4:35,784,995...35,803,474
Ensembl chr 4:35,785,237...35,803,423
|
|
G |
Ass1 |
argininosuccinate synthase 1 |
increases expression |
ISO |
fenpyroximate results in increased expression of ASS1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 3:14,747,355...14,796,909
Ensembl chr 3:14,747,368...14,796,903
|
|
G |
Atf4 |
activating transcription factor 4 |
increases expression |
ISO |
fenpyroximate results in increased expression of ATF4 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446
|
|
G |
Atf5 |
activating transcription factor 5 |
increases expression |
ISO |
fenpyroximate results in increased expression of ATF5 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:95,295,602...95,299,755
Ensembl chr 1:95,295,610...95,299,707
|
|
G |
Atmin |
ATM interactor |
decreases expression |
ISO |
fenpyroximate results in decreased expression of ATMIN mRNA |
CTD |
PMID:33512557 |
|
NCBI chr19:44,996,506...45,013,606
Ensembl chr19:44,996,356...45,013,605
|
|
G |
Atp5f1b |
ATP synthase F1 subunit beta |
decreases expression |
ISO |
fenpyroximate results in decreased expression of ATP5F1B mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 7:515,454...521,858
Ensembl chr 7:515,460...567,273
|
|
G |
Atp5f1c |
ATP synthase F1 subunit gamma |
decreases expression |
ISO |
fenpyroximate results in decreased expression of ATP5F1C mRNA |
CTD |
PMID:33512557 |
|
NCBI chr17:68,423,927...68,446,169
Ensembl chr17:68,423,909...68,608,367
|
|
G |
Atp6v1b2 |
ATPase H+ transporting V1 subunit B2 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of ATP6V1B2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr16:20,617,515...20,641,651
Ensembl chr16:20,617,518...20,641,745
|
|
G |
Aurka |
aurora kinase A |
increases expression |
ISO |
fenpyroximate results in increased expression of AURKA mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 3:161,128,309...161,144,524
Ensembl chr 3:161,128,313...161,144,390
|
|
G |
B2m |
beta-2 microglobulin |
increases expression |
ISO |
fenpyroximate results in increased expression of B2M mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 3:109,095,740...109,101,764
Ensembl chr 3:109,095,729...109,101,766
|
|
G |
B3galt6 |
Beta-1,3-galactosyltransferase 6 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of B3GALT6 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 5:166,584,202...166,586,338
Ensembl chr 5:166,584,202...166,586,338
|
|
G |
Bcl2l13 |
Bcl2-like 13 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of BCL2L13 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 4:154,056,116...154,112,890
Ensembl chr 4:154,056,127...154,108,985
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
increases expression |
ISO |
fenpyroximate results in increased expression of BIRC5 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Bmf |
Bcl2 modifying factor |
decreases expression |
ISO |
fenpyroximate results in decreased expression of BMF mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 3:105,499,534...105,520,159
Ensembl chr 3:105,499,538...105,520,145
|
|
G |
Bphl |
biphenyl hydrolase like |
decreases expression |
ISO |
fenpyroximate results in decreased expression of BPHL mRNA |
CTD |
PMID:33512557 |
|
NCBI chr17:30,800,939...30,837,277
Ensembl chr17:30,799,629...30,837,288
|
|
G |
Bzw1 |
basic leucine zipper and W2 domains 1 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of BZW1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 9:59,930,672...59,944,468
Ensembl chr 9:59,930,744...59,944,430
|
|
G |
C2cd5 |
C2 calcium-dependent domain containing 5 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of C2CD5 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 4:175,969,544...176,055,597
Ensembl chr 4:175,969,545...176,055,558
|
|
G |
Canx |
calnexin |
increases expression |
ISO |
fenpyroximate results in increased expression of CANX mRNA |
CTD |
PMID:33512557 |
|
NCBI chr10:34,623,865...34,656,866
Ensembl chr10:34,625,191...34,656,821
|
|
G |
Cars1 |
cysteinyl-tRNA synthetase 1 |
increases expression |
ISO |
fenpyroximate results in increased expression of CARS1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:198,753,689...198,796,016
Ensembl chr 1:198,753,691...198,795,941
|
|
G |
Casp3 |
caspase 3 |
increases activity |
ISO |
fenpyroximate results in increased activity of CASP3 protein |
CTD |
PMID:35580743 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cat |
catalase |
increases activity |
ISO EXP |
fenpyroximate results in increased activity of CAT protein |
CTD |
PMID:35580743 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cbr1 |
carbonyl reductase 1 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of CBR1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr11:32,860,618...32,862,981
Ensembl chr11:32,908,950...32,911,393 Ensembl chr11:32,908,950...32,911,393
|
|
G |
Cbx4 |
chromobox 4 |
increases expression |
ISO |
fenpyroximate results in increased expression of CBX4 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr10:104,337,140...104,343,210
Ensembl chr10:104,336,876...104,356,706
|
|
G |
Ccnb1 |
cyclin B1 |
increases expression |
ISO |
fenpyroximate results in increased expression of CCNB1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
|
|
G |
Ccnb2 |
cyclin B2 |
increases expression |
ISO |
fenpyroximate results in increased expression of CCNB2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 8:71,087,594...71,100,794
Ensembl chr 8:71,087,595...71,100,874
|
|
G |
Cd24 |
CD24 molecule |
decreases expression |
ISO |
fenpyroximate results in decreased expression of CD24 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr20:47,074,353...47,079,662
Ensembl chr20:47,073,512...47,079,662
|
|
G |
Cdh10 |
cadherin 10 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of CDH10 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 2:68,628,623...68,850,995
Ensembl chr 2:68,628,780...68,850,995
|
|
G |
Cdh2 |
cadherin 2 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of CDH2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr18:7,776,704...7,990,934
Ensembl chr18:7,776,704...7,990,167
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
increases expression |
ISO |
fenpyroximate results in increased expression of CDK1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
|
|
G |
Cdk5r1 |
cyclin-dependent kinase 5 regulatory subunit 1 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of CDK5R1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr10:65,484,266...65,485,467
Ensembl chr10:65,483,941...65,488,456
|
|
G |
Cdk6 |
cyclin-dependent kinase 6 |
increases expression |
ISO |
fenpyroximate results in increased expression of CDK6 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 4:30,637,650...30,829,688
Ensembl chr 4:30,646,460...30,829,634
|
|
G |
Cdkn3 |
cyclin-dependent kinase inhibitor 3 |
increases expression |
ISO |
fenpyroximate results in increased expression of CDKN3 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr15:20,022,522...20,033,948
Ensembl chr15:20,022,664...20,033,945
|
|
G |
Cebpb |
CCAAT/enhancer binding protein beta |
increases expression |
ISO |
fenpyroximate results in increased expression of CEBPB mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473
|
|
G |
Cel |
carboxyl ester lipase |
decreases expression |
ISO |
fenpyroximate results in decreased expression of CEL mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 3:11,883,532...11,891,035
Ensembl chr 3:11,883,532...11,891,035
|
|
G |
Cfl2 |
cofilin 2 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of CFL2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 6:72,355,664...72,359,709
Ensembl chr 6:72,355,664...72,359,674
|
|
G |
Chac1 |
ChaC glutathione-specific gamma-glutamylcyclotransferase 1 |
increases expression |
ISO |
fenpyroximate results in increased expression of CHAC1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 3:106,342,302...106,345,526
Ensembl chr 3:106,342,302...106,345,526
|
|
G |
Chek1 |
checkpoint kinase 1 |
increases expression |
ISO |
fenpyroximate results in increased expression of CHEK1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 8:36,420,565...36,443,477
Ensembl chr 8:36,420,569...36,441,009
|
|
G |
Chka |
choline kinase alpha |
increases expression |
ISO |
fenpyroximate results in increased expression of CHKA mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:201,076,804...201,125,517
Ensembl chr 1:201,076,860...201,125,516
|
|
G |
Cks1b |
CDC28 protein kinase regulatory subunit 1B |
increases expression |
ISO |
fenpyroximate results in increased expression of CKS1B mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 2:174,833,025...174,837,614
Ensembl chr 2:174,833,050...174,837,636
|
|
G |
Cks2 |
CDC28 protein kinase regulatory subunit 2 |
increases expression |
ISO |
fenpyroximate results in increased expression of CKS2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr17:13,570,611...13,575,770
|
|
G |
Clic4 |
chloride intracellular channel 4 |
increases expression |
ISO |
fenpyroximate results in increased expression of CLIC4 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 5:147,456,819...147,513,278
Ensembl chr 5:147,453,712...147,513,452
|
|
G |
Cnpy3 |
canopy FGF signaling regulator 3 |
increases expression |
ISO |
fenpyroximate results in increased expression of CNPY3 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 9:14,233,478...14,247,847
Ensembl chr 9:14,233,428...14,247,831
|
|
G |
Cntn1 |
contactin 1 |
increases expression |
ISO |
fenpyroximate results in increased expression of CNTN1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 7:123,263,146...123,560,896
Ensembl chr 7:123,372,792...123,558,541
|
|
G |
Coa6 |
cytochrome c oxidase assembly factor 6 |
increases expression |
ISO |
fenpyroximate results in increased expression of COA6 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr19:54,395,682...54,398,918
Ensembl chr19:54,395,742...54,399,407
|
|
G |
Col16a1 |
collagen type XVI alpha 1 chain |
increases expression |
ISO |
fenpyroximate results in increased expression of COL16A1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 5:142,388,376...142,442,825
Ensembl chr 5:142,388,426...142,442,825
|
|
G |
Cops5 |
COP9 signalosome subunit 5 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of COPS5 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 5:9,192,233...9,210,498
Ensembl chr 5:9,192,100...9,210,731
|
|
G |
Crebrf |
CREB3 regulatory factor |
increases expression |
ISO |
fenpyroximate results in increased expression of CREBRF mRNA |
CTD |
PMID:33512557 |
|
NCBI chr10:16,399,170...16,479,650
Ensembl chr10:16,404,596...16,461,999
|
|
G |
Creg1 |
cellular repressor of E1A-stimulated genes 1 |
increases expression |
ISO |
fenpyroximate results in increased expression of CREG1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr13:78,019,814...78,032,310
Ensembl chr13:78,019,843...78,032,308
|
|
G |
Creld2 |
cysteine-rich with EGF-like domains 2 |
increases expression |
ISO |
fenpyroximate results in increased expression of CRELD2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 7:119,909,626...119,916,556
Ensembl chr 7:119,909,633...119,916,543
|
|
G |
Crtap |
cartilage associated protein |
increases expression |
ISO |
fenpyroximate results in increased expression of CRTAP mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 8:114,047,929...114,067,648
Ensembl chr 8:114,047,933...114,067,631
|
|
G |
Ctnnal1 |
catenin alpha-like 1 |
increases expression |
ISO |
fenpyroximate results in increased expression of CTNNAL1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 5:71,514,340...71,569,431
Ensembl chr 5:71,514,340...71,569,431
|
|
G |
Ctnnd1 |
catenin delta 1 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of CTNND1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 3:69,683,328...69,734,550
Ensembl chr 3:69,683,313...69,734,516
|
|
G |
Ctps1 |
CTP synthase 1 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of CTPS1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 5:134,125,022...134,154,155
Ensembl chr 5:134,125,025...134,154,180
|
|
G |
Cttn |
cortactin |
decreases expression |
ISO |
fenpyroximate results in decreased expression of CTTN mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:199,599,710...199,635,254
Ensembl chr 1:199,599,710...199,635,164
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases expression |
ISO |
fenpyroximate results in increased expression of CYP1A1 mRNA |
CTD |
PMID:32194361 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp2c6v1 |
cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of CYP2C19 protein |
CTD |
PMID:32194361 |
|
NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
increases expression |
ISO |
fenpyroximate results in increased expression of CYP3A5 mRNA |
CTD |
PMID:34642769 |
|
NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of CYP7A1 mRNA; fenpyroximate results in decreased expression of CYP7A1 protein |
CTD |
PMID:32194361 |
|
NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688
|
|
G |
Daam1 |
dishevelled associated activator of morphogenesis 1 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of DAAM1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 6:90,389,544...90,550,114
Ensembl chr 6:90,389,688...90,550,114
|
|
G |
Daxx |
death-domain associated protein |
decreases expression |
ISO |
fenpyroximate results in decreased expression of DAXX mRNA |
CTD |
PMID:33512557 |
|
NCBI chr20:4,970,090...4,976,145
Ensembl chr20:4,970,092...4,975,843
|
|
G |
Dck |
deoxycytidine kinase |
decreases expression |
ISO |
fenpyroximate results in decreased expression of DCK mRNA |
CTD |
PMID:33512557 |
|
NCBI chr14:19,305,218...19,326,247
Ensembl chr14:19,305,218...19,326,247
|
|
G |
Ddc |
dopa decarboxylase |
decreases expression |
ISO |
fenpyroximate results in decreased expression of DDC mRNA |
CTD |
PMID:34642769 |
|
NCBI chr14:86,378,685...86,469,189
Ensembl chr14:86,378,685...86,469,208
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression |
ISO |
fenpyroximate results in increased expression of DDIT3 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Depdc1b |
DEP domain containing 1B |
increases expression |
ISO |
fenpyroximate results in increased expression of DEPDC1B mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 2:39,891,163...39,963,779
Ensembl chr 2:39,891,481...39,963,779
|
|
G |
Dffb |
DNA fragmentation factor subunit beta |
decreases expression |
ISO |
fenpyroximate results in decreased expression of DFFB mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 5:164,522,446...164,534,733
Ensembl chr 5:164,522,463...164,534,628
|
|
G |
Dlgap5 |
DLG associated protein 5 |
increases expression |
ISO |
fenpyroximate results in increased expression of DLGAP5 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr15:20,633,964...20,664,569
Ensembl chr15:20,633,966...20,664,518
|
|
G |
Dnajb14 |
DnaJ heat shock protein family (Hsp40) member B14 |
increases expression |
ISO |
fenpyroximate results in increased expression of DNAJB14 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 2:226,358,988...226,409,461
Ensembl chr 2:226,358,996...226,402,490
|
|
G |
Dnttip2 |
deoxynucleotidyltransferase, terminal, interacting protein 2 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of DNTTIP2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 2:210,374,240...210,386,366
Ensembl chr 2:210,374,289...210,385,581
|
|
G |
Drd2 |
dopamine receptor D2 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of DRD2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 8:49,708,903...49,772,888
Ensembl chr 8:49,708,927...49,772,875
|
|
G |
Dusp4 |
dual specificity phosphatase 4 |
increases expression |
ISO |
fenpyroximate results in increased expression of DUSP4 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr16:57,376,659...57,398,161
Ensembl chr16:57,377,229...57,398,138
|
|
G |
Eef1g |
eukaryotic translation elongation factor 1 gamma |
decreases expression |
ISO |
fenpyroximate results in decreased expression of EEF1G mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:205,860,713...205,871,319
Ensembl chr 1:205,860,698...205,872,382
|
|
G |
Egr1 |
early growth response 1 |
increases expression |
ISO |
fenpyroximate results in increased expression of EGR1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr18:26,463,333...26,465,531
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Eif2s2 |
eukaryotic translation initiation factor 2 subunit beta |
increases expression |
ISO |
fenpyroximate results in increased expression of EIF2S2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 3:143,374,652...143,395,460
Ensembl chr 3:143,373,686...143,395,432
|
|
G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
increases expression |
ISO |
fenpyroximate results in increased expression of EIF4EBP1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984
|
|
G |
Elmod1 |
ELMO domain containing 1 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of ELMOD1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 8:54,298,363...54,355,348
Ensembl chr 8:54,298,363...54,355,140
|
|
G |
Ep300 |
E1A binding protein p300 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of EP300 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 7:113,108,476...113,178,529
Ensembl chr 7:113,106,247...113,136,088 Ensembl chr 7:113,106,247...113,136,088
|
|
G |
Ephb2 |
Eph receptor B2 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of EPHB2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 5:148,889,574...149,077,027
Ensembl chr 5:148,897,246...149,077,059
|
|
G |
Ero1a |
endoplasmic reticulum oxidoreductase 1 alpha |
increases expression |
ISO |
fenpyroximate results in increased expression of ERO1A mRNA |
CTD |
PMID:33512557 |
|
NCBI chr15:18,495,037...18,530,440
Ensembl chr15:18,492,945...18,530,478
|
|
G |
Ero1b |
endoplasmic reticulum oxidoreductase 1 beta |
increases expression |
ISO |
fenpyroximate results in increased expression of ERO1B mRNA |
CTD |
PMID:33512557 |
|
NCBI chr17:85,861,086...86,003,244
Ensembl chr17:85,929,618...86,003,398
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions |
ISO |
fenpyroximate inhibits the reaction [Estradiol results in increased activity of ESR2 protein] |
CTD |
PMID:30818834 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Esrra |
estrogen related receptor, alpha |
multiple interactions |
ISO |
fenpyroximate inhibits the reaction [PPARGC1A protein results in increased activity of ESRRA protein]; fenpyroximate inhibits the reaction [XCT790 results in decreased activity of ESRRA protein] |
CTD |
PMID:30818834 |
|
NCBI chr 1:204,104,100...204,114,182
Ensembl chr 1:204,104,101...204,114,268
|
|
G |
Exosc4 |
exosome component 4 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of EXOSC4 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 7:108,047,831...108,050,573
Ensembl chr 7:108,047,831...108,050,573
|
|
G |
Exosc8 |
exosome component 8 |
increases expression |
ISO |
fenpyroximate results in increased expression of EXOSC8 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 2:138,930,405...138,937,009
Ensembl chr 2:138,930,405...138,936,928
|
|
G |
Fam72a |
family with sequence similarity 72, member A |
increases expression |
ISO |
fenpyroximate results in increased expression of FAM72A mRNA |
CTD |
PMID:33512557 |
|
NCBI chr13:42,968,409...42,978,976
Ensembl chr13:42,967,578...42,984,208
|
|
G |
Fbl |
fibrillarin |
increases expression |
ISO |
fenpyroximate results in increased expression of FBL mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:83,469,832...83,478,932
Ensembl chr 1:83,469,832...83,478,932
|
|
G |
Fbxo7 |
F-box protein 7 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of FBXO7 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 7:17,809,224...17,837,549
Ensembl chr 7:17,809,231...17,837,530
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
increases expression |
ISO |
fenpyroximate results in increased expression of FGF2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221
|
|
G |
Fth1 |
ferritin heavy chain 1 |
increases expression |
ISO |
fenpyroximate results in increased expression of FTH1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:206,627,142...206,629,430
Ensembl chr 1:206,627,103...206,725,424
|
|
G |
Ftl1 |
ferritin light chain 1 |
increases expression |
ISO |
fenpyroximate results in increased expression of FTL mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:95,936,390...95,938,234
Ensembl chr 1:95,936,387...95,939,725 Ensembl chr10:95,936,387...95,939,725
|
|
G |
G6pc1 |
glucose-6-phosphatase catalytic subunit 1 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of G6PC1 mRNA |
CTD |
PMID:32194361 |
|
NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804
|
|
G |
G6pd |
glucose-6-phosphate dehydrogenase |
decreases expression |
ISO |
fenpyroximate results in decreased expression of G6PD mRNA |
CTD |
PMID:33512557 |
|
NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801
|
|
G |
Gadd45b |
growth arrest and DNA-damage-inducible, beta |
increases expression |
ISO |
fenpyroximate results in increased expression of GADD45B mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 7:8,778,004...8,780,306
Ensembl chr 7:8,778,007...8,780,046
|
|
G |
Gadd45g |
growth arrest and DNA-damage-inducible, gamma |
increases expression |
ISO |
fenpyroximate results in increased expression of GADD45G mRNA |
CTD |
PMID:33512557 |
|
NCBI chr17:13,376,842...13,378,587
Ensembl chr17:13,376,839...13,378,610
|
|
G |
Gap43 |
growth associated protein 43 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of GAP43 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr11:58,376,371...58,470,047
Ensembl chr11:58,376,371...58,470,045
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
increases expression |
ISO |
fenpyroximate results in increased expression of GCLM mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535
|
|
G |
Gdf15 |
growth differentiation factor 15 |
increases expression |
ISO |
fenpyroximate results in increased expression of GDF15 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr16:18,805,312...18,807,893
Ensembl chr16:18,805,239...18,808,055
|
|
G |
Gfus |
GDP-L-fucose synthase |
increases expression |
ISO |
fenpyroximate results in increased expression of GFUS mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 7:107,612,087...107,617,005
Ensembl chr 7:107,612,094...107,616,948
|
|
G |
Gldc |
glycine decarboxylase |
decreases expression |
ISO |
fenpyroximate results in decreased expression of GLDC mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:227,883,247...227,962,119
Ensembl chr 1:227,883,249...227,962,097
|
|
G |
Gli3 |
GLI family zinc finger 3 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of GLI3 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr17:49,438,567...49,709,712
Ensembl chr17:49,438,567...49,709,712
|
|
G |
Glrx |
glutaredoxin |
decreases expression |
ISO |
fenpyroximate results in decreased expression of GLRX mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 2:5,341,873...5,351,686
Ensembl chr 2:5,341,885...5,351,680
|
|
G |
Gnai2 |
G protein subunit alpha i2 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of GNAI2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 8:108,288,401...108,309,009
Ensembl chr 8:108,288,401...108,308,979
|
|
G |
Grb10 |
growth factor receptor bound protein 10 |
increases expression |
ISO |
fenpyroximate results in increased expression of GRB10 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr14:86,495,054...86,602,815
Ensembl chr14:86,495,054...86,602,806
|
|
G |
Grm4 |
glutamate metabotropic receptor 4 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of GRM4 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr20:5,484,172...5,572,821
Ensembl chr20:5,481,124...5,572,821
|
|
G |
Gstm2 |
glutathione S-transferase mu 2 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of GSTM2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 2:195,624,015...195,628,774
Ensembl chr 2:195,544,426...195,628,961
|
|
G |
H1f2 |
H1.2 linker histone, cluster member |
increases expression |
ISO |
fenpyroximate results in increased expression of H1-2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr17:41,391,106...41,392,611
Ensembl chr17:41,388,477...41,392,635
|
|
G |
H2bc9 |
H2B clustered histone 9 |
increases expression |
ISO |
fenpyroximate results in increased expression of H2BC9 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr17:42,470,593...42,478,605
|
|
G |
Hapstr1 |
HUWE1 associated protein modifying stress responses |
increases expression |
ISO |
fenpyroximate results in increased expression of HAPSTR1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr10:6,746,037...6,774,992
Ensembl chr10:6,746,048...6,774,992
|
|
G |
Hcst |
hematopoietic cell signal transducer |
increases expression |
ISO |
fenpyroximate results in increased expression of HCST mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:85,676,976...85,679,083
Ensembl chr 1:85,676,979...85,679,012
|
|
G |
Hdac2 |
histone deacetylase 2 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of HDAC2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr20:40,548,250...40,571,609
Ensembl chr20:40,548,250...40,571,609
|
|
G |
Herpud1 |
homocysteine inducible ER protein with ubiquitin like domain 1 |
increases expression |
ISO |
fenpyroximate results in increased expression of HERPUD1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr19:10,598,411...10,609,002
Ensembl chr19:10,598,417...10,618,424
|
|
G |
Hes1 |
hes family bHLH transcription factor 1 |
increases expression |
ISO |
fenpyroximate results in increased expression of HES1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr11:70,705,763...70,708,176
Ensembl chr11:70,705,764...70,708,192
|
|
G |
Hist1h2af |
histone cluster 1 H2A family member F |
increases expression |
ISO |
fenpyroximate results in increased expression of H2AC8 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr17:41,379,404...41,379,796
Ensembl chr17:41,379,404...41,379,796
|
|
G |
Hist1h2ah |
histone cluster 1 H2A family member H |
increases expression |
ISO |
fenpyroximate results in increased expression of H2AC11 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr17:41,384,521...41,385,018
|
|
G |
Hist1h2bd |
histone cluster 1 H2B family member D |
increases expression |
ISO |
fenpyroximate results in increased expression of H2BC5 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr17:42,792,887...42,793,268
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression |
ISO |
fenpyroximate results in increased expression of HMOX1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hnrnpm |
heterogeneous nuclear ribonucleoprotein M |
decreases expression |
ISO |
fenpyroximate results in decreased expression of HNRNPM mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 7:14,438,703...14,476,781
Ensembl chr 7:14,438,688...14,476,762
|
|
G |
Hsp90b1 |
heat shock protein 90 beta family member 1 |
increases expression |
ISO |
fenpyroximate results in increased expression of HSP90B1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 7:21,110,431...21,124,762
Ensembl chr 7:21,110,457...21,124,788
|
|
G |
Hspa1a |
heat shock protein family A (Hsp70) member 1A |
increases expression |
ISO |
fenpyroximate results in increased expression of HSPA1B mRNA |
CTD |
PMID:33512557 |
|
NCBI chr20:3,855,104...3,859,148
Ensembl chr20:3,856,006...3,873,240
|
|
G |
Hspe1 |
heat shock protein family E (Hsp10) member 1 |
increases expression |
ISO |
fenpyroximate results in increased expression of HSPE1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 9:56,589,912...56,593,000
Ensembl chr 9:56,589,789...56,593,089
|
|
G |
Htatsf1 |
HIV-1 Tat specific factor 1 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of HTATSF1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr X:134,935,426...134,949,607
Ensembl chr X:134,935,426...134,949,607
|
|
G |
Id1 |
inhibitor of DNA binding 1 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of ID1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 3:141,210,666...141,212,420
Ensembl chr 3:141,211,267...141,212,419
|
|
G |
Id2 |
inhibitor of DNA binding 2 |
increases expression |
ISO |
fenpyroximate results in increased expression of ID2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 6:41,740,556...41,742,393
Ensembl chr 6:41,728,946...41,744,400
|
|
G |
Ifrd1 |
interferon-related developmental regulator 1 |
increases expression |
ISO |
fenpyroximate results in increased expression of IFRD1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 6:57,269,395...57,317,833
Ensembl chr 6:57,269,384...57,288,990
|
|
G |
Igf1r |
insulin-like growth factor 1 receptor |
decreases expression |
ISO |
fenpyroximate results in decreased expression of IGF1R mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:121,549,839...121,838,545
Ensembl chr 1:121,550,743...121,831,777
|
|
G |
Igfbp2 |
insulin-like growth factor binding protein 2 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of IGFBP2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 9:74,415,574...74,442,945
Ensembl chr 9:74,415,546...74,442,937
|
|
G |
Ina |
internexin neuronal intermediate filament protein, alpha |
decreases expression |
ISO |
fenpyroximate results in decreased expression of INA mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:245,896,775...245,908,330
Ensembl chr 1:245,896,775...245,908,330
|
|
G |
Ipo5 |
importin 5 |
increases expression |
ISO |
fenpyroximate results in increased expression of IPO5 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr15:97,990,755...98,041,074
Ensembl chr15:98,005,299...98,041,126
|
|
G |
Itpr2 |
inositol 1,4,5-trisphosphate receptor, type 2 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of ITPR2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 4:179,028,594...179,434,657
Ensembl chr 4:179,027,281...179,404,164
|
|
G |
Jmjd6 |
jumonji domain containing 6, arginine demethylase and lysine hydroxylase |
increases expression |
ISO |
fenpyroximate results in increased expression of JMJD6 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr10:102,041,131...102,047,182
Ensembl chr10:102,041,120...102,047,182
|
|
G |
Kdm3a |
lysine demethylase 3A |
decreases expression |
ISO |
fenpyroximate results in decreased expression of KDM3A mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 4:103,630,907...103,675,073
Ensembl chr 4:103,630,908...103,675,073
|
|
G |
Kdm5b |
lysine demethylase 5B |
decreases expression |
ISO |
fenpyroximate results in decreased expression of KDM5B mRNA |
CTD |
PMID:33512557 |
|
NCBI chr13:46,001,589...46,073,868
Ensembl chr13:46,002,542...46,073,872
|
|
G |
Kif15 |
kinesin family member 15 |
increases expression |
ISO |
fenpyroximate results in increased expression of KIF15 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 8:122,601,888...122,672,750
Ensembl chr 8:122,601,897...122,672,750
|
|
G |
Kif20a |
kinesin family member 20A |
increases expression |
ISO |
fenpyroximate results in increased expression of KIF20A mRNA |
CTD |
PMID:33512557 |
|
NCBI chr18:26,230,294...26,238,780
Ensembl chr18:26,230,230...26,238,780
|
|
G |
Kif5c |
kinesin family member 5C |
decreases expression |
ISO |
fenpyroximate results in decreased expression of KIF5C mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 3:34,032,082...34,185,597
Ensembl chr 3:34,032,105...34,182,413
|
|
G |
Klhl24 |
kelch-like family member 24 |
increases expression |
ISO |
fenpyroximate results in increased expression of KLHL24 mRNA |
CTD |
PMID:34642769 |
|
NCBI chr11:80,843,621...80,877,693
Ensembl chr11:80,846,755...80,877,636
|
|
G |
Knl1 |
kinetochore scaffold 1 |
increases expression |
ISO |
fenpyroximate results in increased expression of KNL1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 3:106,029,627...106,091,915
Ensembl chr 3:106,029,661...106,091,915
|
|
G |
Kyat3 |
kynurenine aminotransferase 3 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of KYAT3 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 2:231,701,881...231,747,462
Ensembl chr 2:231,701,963...231,747,227
|
|
G |
LOC102549061 |
histone H2B type 1-N-like |
increases expression |
ISO |
fenpyroximate results in increased expression of H2BC3 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr17:41,380,058...41,380,685
|
|
G |
LOC103690190 |
histone H2A type 1-E |
increases expression |
ISO |
fenpyroximate results in increased expression of H2AC6 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr17:42,707,863...42,708,420
|
|
G |
LOC684841 |
similar to CG31613-PA |
increases expression |
ISO |
fenpyroximate results in increased expression of H3C10 mRNA |
CTD |
PMID:33512557 |
|
|
|
G |
Loxl1 |
lysyl oxidase-like 1 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of LOXL1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 8:58,692,592...58,716,356
Ensembl chr 8:58,692,593...58,716,356
|
|
G |
Lrrc41 |
leucine rich repeat containing 41 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of LRRC41 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 5:129,554,547...129,575,450
Ensembl chr 5:129,554,547...129,575,449
|
|
G |
Manf |
mesencephalic astrocyte-derived neurotrophic factor |
increases expression |
ISO |
fenpyroximate results in increased expression of MANF mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 8:107,500,856...107,551,595
Ensembl chr 8:107,548,352...107,551,438
|
|
G |
Map1b |
microtubule-associated protein 1B |
decreases expression |
ISO |
fenpyroximate results in decreased expression of MAP1B mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 2:30,817,261...30,910,458
Ensembl chr 2:30,817,261...30,910,317
|
|
G |
Map6 |
microtubule-associated protein 6 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of MAP6 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:153,568,019...153,634,415
Ensembl chr 1:153,568,368...153,634,414
|
|
G |
Mcm7 |
minichromosome maintenance complex component 7 |
increases expression |
ISO |
fenpyroximate results in increased expression of MCM7 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr12:17,042,207...17,049,470
Ensembl chr12:17,042,212...17,050,063
|
|
G |
Mdk |
midkine |
increases expression |
ISO |
fenpyroximate results in increased expression of MDK mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 3:77,901,156...77,903,997
Ensembl chr 3:77,901,158...77,903,130
|
|
G |
Me1 |
malic enzyme 1 |
increases expression |
ISO |
fenpyroximate results in increased expression of ME1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 8:87,549,043...87,660,251
Ensembl chr 8:87,549,043...87,660,304
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
increases expression |
ISO |
fenpyroximate results in increased expression of MKI67 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762
|
|
G |
Mllt11 |
MLLT11, transcription factor 7 cofactor |
decreases expression |
ISO |
fenpyroximate results in decreased expression of MLLT11 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 2:182,795,790...182,804,960
Ensembl chr 2:182,795,790...182,797,199
|
|
G |
Mnat1 |
MNAT1 component of CDK activating kinase |
decreases expression |
ISO |
fenpyroximate results in decreased expression of MNAT1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 6:91,814,703...91,971,945
Ensembl chr 6:91,814,749...91,970,744
|
|
G |
Morn2 |
MORN repeat containing 2 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of MORN2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 6:14,718,799...14,725,281
|
|
G |
Msi2 |
musashi RNA-binding protein 2 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of MSI2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr10:73,143,760...73,510,566
Ensembl chr10:73,147,380...73,510,157
|
|
G |
Mta1 |
metastasis associated 1 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of MTA1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 6:132,178,608...132,217,641
Ensembl chr 6:132,178,853...132,217,641
|
|
G |
Mthfd2 |
methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase |
increases expression |
ISO |
fenpyroximate results in increased expression of MTHFD2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 4:115,811,135...115,822,663
Ensembl chr 4:115,811,139...115,822,608
|
|
G |
Nav1 |
neuron navigator 1 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of NAV1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr13:46,866,972...47,119,368
Ensembl chr13:46,873,689...47,126,449
|
|
G |
Ncan |
neurocan |
decreases expression |
ISO |
fenpyroximate results in decreased expression of NCAN mRNA |
CTD |
PMID:33512557 |
|
NCBI chr16:19,301,969...19,328,436
Ensembl chr16:19,301,969...19,328,436
|
|
G |
Ndufa1 |
NADH:ubiquinone oxidoreductase subunit A1 |
increases expression |
ISO |
fenpyroximate results in increased expression of NDUFA1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr X:116,424,223...116,427,875
Ensembl chr X:116,424,223...116,428,633
|
|
G |
Nek2 |
NIMA-related kinase 2 |
increases expression |
ISO |
fenpyroximate results in increased expression of NEK2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr13:103,405,818...103,419,063
Ensembl chr13:103,405,819...103,419,051
|
|
G |
Nfatc3 |
nuclear factor of activated T-cells 3 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of NFATC3 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr19:33,960,643...34,035,150
Ensembl chr19:33,960,852...34,035,150
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
increases activity |
ISO |
fenpyroximate results in increased activity of NFE2L2 protein |
CTD |
PMID:30818834 |
|
NCBI chr 3:60,594,239...60,621,785
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfil3 |
nuclear factor, interleukin 3 regulated |
decreases expression |
ISO |
fenpyroximate results in decreased expression of NFIL3 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr17:12,280,499...12,295,728
Ensembl chr17:12,280,484...12,295,858
|
|
G |
Nfkbib |
NFKB inhibitor beta |
decreases expression |
ISO |
fenpyroximate results in decreased expression of NFKBIB mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:84,046,292...84,053,862
Ensembl chr 1:84,046,295...84,053,862
|
|
G |
Nit1 |
nitrilase 1 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of NIT1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr13:83,769,888...83,773,324
Ensembl chr13:83,765,941...83,773,332
|
|
G |
Nmnat3 |
nicotinamide nucleotide adenylyltransferase 3 |
decreases response to substance |
ISO |
NMNAT3 protein results in decreased susceptibility to fenpyroximate |
CTD |
PMID:18463239 |
|
NCBI chr 8:98,892,168...99,003,912
Ensembl chr 8:98,873,398...99,020,645
|
|
G |
Nos3 |
nitric oxide synthase 3 |
increases expression |
ISO |
fenpyroximate results in increased expression of NOS3 mRNA |
CTD |
PMID:34642769 |
|
NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
|
|
G |
Notch3 |
notch receptor 3 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of NOTCH3 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 7:11,132,984...11,184,025
Ensembl chr 7:11,133,706...11,184,025
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
increases expression |
ISO |
fenpyroximate results in increased expression of NQO1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nr2f1 |
nuclear receptor subfamily 2, group F, member 1 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of NR2F1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 2:8,040,375...8,050,123
Ensembl chr 2:8,040,377...8,050,123
|
|
G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
increases expression |
ISO |
fenpyroximate results in increased expression of NR3C1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr18:31,271,681...31,393,320
Ensembl chr18:31,271,681...31,393,375
|
|
G |
Nr5a1 |
nuclear receptor subfamily 5, group A, member 1 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of NR5A1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 3:22,464,786...22,486,328
Ensembl chr 3:22,465,502...22,486,328
|
|
G |
Nrcam |
neuronal cell adhesion molecule |
decreases expression |
ISO |
fenpyroximate results in decreased expression of NRCAM mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 6:61,402,813...61,698,536
Ensembl chr 6:61,329,863...61,702,992
|
|
G |
Nrxn1 |
neurexin 1 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of NRXN1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 6:3,177,788...4,323,848
Ensembl chr 6:3,177,897...4,322,710
|
|
G |
Ntrk1 |
neurotrophic receptor tyrosine kinase 1 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of NTRK1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 2:173,236,961...173,253,806
Ensembl chr 2:173,236,963...173,253,770
|
|
G |
Oaz1 |
ornithine decarboxylase antizyme 1 |
increases expression |
ISO |
fenpyroximate results in increased expression of OAZ1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 7:8,883,855...8,886,315
Ensembl chr 7:8,883,851...8,886,310
|
|
G |
Olfml2b |
olfactomedin-like 2B |
decreases expression |
ISO |
fenpyroximate results in decreased expression of OLFML2B mRNA |
CTD |
PMID:33512557 |
|
NCBI chr13:82,869,414...82,906,607
Ensembl chr13:82,869,433...82,906,607
|
|
G |
Ostc |
oligosaccharyltransferase complex non-catalytic subunit |
increases expression |
ISO |
fenpyroximate results in increased expression of OSTC mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 2:219,250,549...219,266,076
Ensembl chr 2:219,236,952...219,266,107
|
|
G |
Pafah1b3 |
platelet-activating factor acetylhydrolase 1b, catalytic subunit 3 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of PAFAH1B3 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:80,881,263...80,883,789
Ensembl chr 1:80,881,309...80,883,893
|
|
G |
Park7 |
Parkinsonism associated deglycase |
decreases response to substance |
ISO |
PARK7 protein results in decreased susceptibility to fenpyroximate |
CTD |
PMID:21219333 |
|
NCBI chr 5:161,353,718...161,376,993
Ensembl chr 5:161,353,719...161,376,970
|
|
G |
Parp2 |
poly (ADP-ribose) polymerase 2 |
increases expression |
ISO |
fenpyroximate results in increased expression of PARP2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr15:24,034,069...24,044,340
Ensembl chr15:24,034,106...24,044,338
|
|
G |
Pdia6 |
protein disulfide isomerase family A, member 6 |
increases expression |
ISO |
fenpyroximate results in increased expression of PDIA6 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 6:40,062,980...40,080,223
Ensembl chr 6:40,062,926...40,080,613
|
|
G |
Pebp1 |
phosphatidylethanolamine binding protein 1 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of PEBP1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr12:39,302,864...39,307,064
Ensembl chr12:39,302,840...39,307,862
|
|
G |
Peg10 |
paternally expressed 10 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of PEG10 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 4:32,842,394...32,855,641
Ensembl chr 4:32,848,493...32,852,621
|
|
G |
Pfkp |
phosphofructokinase, platelet |
increases expression |
ISO |
fenpyroximate results in increased expression of PFKP mRNA |
CTD |
PMID:34642769 |
|
NCBI chr17:63,729,743...63,794,021
Ensembl chr17:63,729,780...63,794,018
|
|
G |
Pgm3 |
phosphoglucomutase 3 |
increases expression |
ISO |
fenpyroximate results in increased expression of PGM3 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 8:87,517,931...87,536,034
Ensembl chr 8:87,517,701...87,536,022
|
|
G |
Pgr |
progesterone receptor |
multiple interactions |
ISO |
fenpyroximate inhibits the reaction [Promegestone results in increased activity of PGR protein] |
CTD |
PMID:30818834 |
|
NCBI chr 8:6,073,216...6,131,552
Ensembl chr 8:6,072,673...6,131,344
|
|
G |
Phgdh |
phosphoglycerate dehydrogenase |
increases expression |
ISO |
fenpyroximate results in increased expression of PHGDH mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 2:185,906,964...185,936,160
Ensembl chr 2:185,906,966...185,935,944
|
|
G |
Phlda1 |
pleckstrin homology-like domain, family A, member 1 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of PHLDA1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 7:46,967,433...46,969,637
Ensembl chr 7:46,967,409...46,969,861
|
|
G |
Pik3c2b |
phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 beta |
decreases expression |
ISO |
fenpyroximate results in decreased expression of PIK3C2B mRNA |
CTD |
PMID:33512557 |
|
NCBI chr13:44,494,673...44,555,663
Ensembl chr13:44,495,050...44,555,612
|
|
G |
Pink1 |
PTEN induced kinase 1 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of PINK1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 5:150,530,523...150,542,635
Ensembl chr 5:150,530,523...150,542,635
|
|
G |
Pip4k2b |
phosphatidylinositol-5-phosphate 4-kinase type 2 beta |
decreases expression |
ISO |
fenpyroximate results in decreased expression of PIP4K2B mRNA |
CTD |
PMID:33512557 |
|
NCBI chr10:82,706,016...82,734,938
Ensembl chr10:82,701,098...82,734,938
|
|
G |
Pitpna |
phosphatidylinositol transfer protein, alpha |
decreases expression |
ISO |
fenpyroximate results in decreased expression of PITPNA mRNA |
CTD |
PMID:33512557 |
|
NCBI chr10:60,430,712...60,473,564
Ensembl chr10:60,430,748...60,471,342
|
|
G |
Plin2 |
perilipin 2 |
increases expression |
ISO |
fenpyroximate results in increased expression of PLIN2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 5:101,156,643...101,211,738
Ensembl chr 5:101,154,411...101,242,319
|
|
G |
Pole3 |
DNA polymerase epsilon 3, accessory subunit |
increases expression |
ISO |
fenpyroximate results in increased expression of POLE3 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 5:75,973,941...75,977,175
Ensembl chr 5:75,974,717...75,977,231
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
multiple interactions |
ISO |
fenpyroximate inhibits the reaction [PPARGC1A protein results in increased activity of ESRRA protein] |
CTD |
PMID:30818834 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Ppp2r1a |
protein phosphatase 2 scaffold subunit A alpha |
decreases expression |
ISO |
fenpyroximate results in decreased expression of PPP2R1A mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:60,540,223...60,559,467
Ensembl chr 1:60,540,194...60,560,129
|
|
G |
Prkag1 |
protein kinase AMP-activated non-catalytic subunit gamma 1 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of PRKAG1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 7:129,963,105...129,980,532
Ensembl chr 7:129,963,105...129,980,561
|
|
G |
Prkar1a |
protein kinase cAMP-dependent type I regulatory subunit alpha |
decreases expression |
ISO |
fenpyroximate results in decreased expression of PRKAR1A mRNA |
CTD |
PMID:33512557 |
|
NCBI chr10:94,621,042...94,639,534
Ensembl chr10:94,620,039...94,639,041
|
|
G |
Prkn |
parkin RBR E3 ubiquitin protein ligase |
decreases expression |
ISO |
fenpyroximate results in decreased expression of PRKN mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:48,688,651...49,882,520
Ensembl chr 1:48,690,556...49,882,555
|
 | |